US20090105631A1 - Systems and methods for controlling renovascular perfusion - Google Patents
Systems and methods for controlling renovascular perfusion Download PDFInfo
- Publication number
- US20090105631A1 US20090105631A1 US12/345,095 US34509508A US2009105631A1 US 20090105631 A1 US20090105631 A1 US 20090105631A1 US 34509508 A US34509508 A US 34509508A US 2009105631 A1 US2009105631 A1 US 2009105631A1
- Authority
- US
- United States
- Prior art keywords
- renal
- perfusion
- flow
- blood
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/367—Circuit parts not covered by the preceding subgroups of group A61M1/3621
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
Definitions
- the present invention generally relates to medical devices and methods of use for the treatment and/or management of cardiovascular and renal disorders. Specifically, the present invention relates to devices and methods for controlling renal perfusion in the renovascular system for the treatment and/or management of cardiovascular disorders such as hypertension and congestive heart failure, and renal disorders such as renal insufficiency and end stage renal disease.
- Cardiovascular disease is a major contributor to patient illness and mortality. It also is a primary driver of health care expenditure, costing more than $326 billion each year in the United States.
- Hypertension or high blood pressure, is a major cardiovascular disorder that is estimated to affect over 50 million people in the United States alone. Of those with hypertension, it is reported that fewer than 30% have their blood pressure under control.
- Hypertension is a leading cause of heart failure and stroke. It is the primary cause of death in over 42,000 patients per year and is listed as a primary or contributing cause of death in over 200,000 patients per year in the U.S. Accordingly, hypertension is a serious health problem demanding significant research and development for the treatment thereof.
- Hypertension occurs when the body's smaller blood vessels (arterioles) constrict, causing an increase in blood pressure. Because the blood vessels constrict, the heart must work harder to maintain blood flow at the higher pressures. Although the body may tolerate short periods of increased blood pressure, sustained hypertension may eventually result in damage to multiple body organs, including the kidneys, brain, eyes and other tissues, causing a variety of maladies associated therewith. The elevated blood pressure may also damage the lining of the blood vessels, accelerating the process of atherosclerosis and increasing the likelihood that a blood clot may develop. This could lead to a heart attack and/or stroke. Sustained high blood pressure may eventually result in an enlarged and damaged heart (hypertrophy), which may lead to heart failure.
- Heart failure is the final common expression of a variety of cardiovascular disorders, including ischemic heart disease. It is characterized by an inability of the heart to pump enough blood to meet the body's needs and results in fatigue, reduced exercise capacity and poor survival. It is estimated that approximately 5,000,000 people in the United States suffer from heart failure, directly leading to 39,000 deaths per year and contributing to another 225,000 deaths per year. It is also estimated that greater than 400,000 new cases of heart failure are diagnosed each year. Heart failure accounts for over 900,000 hospital admissions annually, and it is the most common discharge diagnosis in patients over the age of 65 years. It has been reported that the cost of treating heart failure in the United States exceeds $20 billion annually. Accordingly, heart failure is also a serious health problem demanding significant research and development for the treatment and/or management thereof.
- End stage renal disease affects over 300,000 people in the United States, with an annual incidence of over 79,000. Death from ESRD occurred in over 60,000 cases in 1998; the five year survival rate is less than 30%. Medicare payments in 1998 for the treatment of ESRD exceeded $10 billion. Accordingly, ESRD is a major health problem demanding improved therapy and management.
- Heart failure results in the activation of a number of body systems to compensate for the heart's inability to pump sufficient blood. Many of these responses are mediated by an increase in the level of activation of the sympathetic nervous system as well as activation of multiple other neurohormonal responses.
- this sympathetic nervous system activation signals the heart to increase heart rate and force of contraction to increase the cardiac output; it signals the kidneys to expand the blood volume by retaining sodium and water; and it signals the arterioles to constrict to elevate to the blood pressure.
- the cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state. Accordingly, it is desirable to reduce the level of sympathetic nervous system and other neurohormonal activation in order to stop or at least minimize this vicious cycle and thereby treat or manage the heart failure.
- vasodilators to reduce the blood pressure and ease the workload of the heart
- diuretics to reduce fluid overload
- inhibitors and blocking agents of the body's neurohormonal responses and other medicaments.
- Heart transplantation has been proposed for patients who suffer from severe, refractory heart failure.
- an implantable medical device such as a ventricular assist device may be implanted in the chest to increase the pumping action of the heart.
- an intra aortic balloon pump may be used for maintaining heart function for short periods of time, but typically no longer than one month.
- Other surgical procedures are available as well.
- each of the therapies has its own disadvantages.
- drug therapy is often incompletely effective. Some patients may be unresponsive (refractory) to medical therapy. Drugs often have unwanted side effects and may need to be given in complex regimens. These and other factors contribute to poor patient compliance with medical therapy. Drug therapy may also be expensive, adding to the health care costs associated with these disorders.
- surgical approaches are very costly, may be associated with significant patient morbidity and mortality and may not alter the natural history of the disease. Accordingly, there continues to be a substantial and long felt need for new devices and methods for treating and/or managing high blood pressure, heart failure and renal disease, as well as their associated complications.
- the present invention provides a number of devices, systems and methods by which the real or apparent renovascular perfusion and the renal interstitial hydrostatic pressure may be selectively and controllably increased.
- the renal system does not experience the reduced perfusion. Because the renal system does not experience the reduced perfusion, it does not initiate or contribute to, and may reduce the neurohormonal activation normally caused by reduced cardiac output and suboptimal renal perfusion, nor does it begin or continue, and could reverse the process of sodium and water retention that also would otherwise result.
- the present invention reduces or reverses neurohormonal activation and fluid retention, and thereby minimizes their deleterious effects on the heart, vasculature, kidneys and other body systems.
- the present invention provides a number of devices, systems and methods by which renal perfusion and pressure can be increased, thereby restoring or augmenting perfusion of the kidney and blood filtration.
- the present invention increases interstitial pressure to reduce sodium and water reabsorption, which have been shown to be interrelated.
- the present invention provides a method of treating a patient utilizing a blood perfusion modification device, one or more physiologic sensors, and a control system.
- the blood perfusion modification device may be positioned in the renovascular circulation or immediately adjacent thereto.
- the sensor is preferably positioned in a renal artery or upstream thereof, but may also be placed in, on or adjacent the patient to generate a signal indicative of the need to modify renal perfusion.
- the sensor may be positioned in a kidney, a renal artery or vein or adjacent thereto to generate a signal indicative of arterial blood perfusion, renal venous pressure or renal interstitial pressure.
- the blood perfusion modification device may be activated, deactivated or otherwise modified as a function of the sensor signal to cause or simulate a change, and preferably an increase, in renal perfusion and/or pressure.
- This method may be used to treat a number of clinical conditions including congestive heart failure, hypertension, renal failure, cardiovascular abnormalities, and the like. In each instance, the method may include the initial step of diagnosing or monitoring the clinical condition or a symptom or sign thereof, and thereafter providing treatment as needed.
- the present invention also provides a system including a blood perfusion modification device (e.g., a flow regulator, a flow redirector or a pump), a physiologic sensor (e.g., a transducer or a gauge), and a control system operably connected to both.
- the blood perfusion modification device is preferably positioned in the renovascular circulation.
- the control system (or a portion thereof) may be implanted or carried externally by the patient.
- the sensor In the closed loop mode, the sensor generates a sensor signal indicative of the need to modify renovascular perfusion, and the control system generates a control signal to activate the modification device as a function of the sensor signal to thereby modify the renovascular circulation.
- the control system In the open loop mode, which may or may not utilize feedback from the sensor, the control system generates a control signal to activate the modification device as dictated by, for example, a pre programmed algorithm, the patient or the physician.
- the sensor may comprise, for example, a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, a thermodilution flow transducer, or a strain gauge.
- the sensor may generate a signal indicative of pressure (e.g., mean, systolic, diastolic or pulse), blood flow velocity, vasoactivity, or other fluid dynamic property.
- the sensor may measure the blood concentration of a component (e.g., sodium, renin, etc.) or an arterial/venous difference in concentration of the component.
- the blood perfusion modification device may comprise a flow regulator positioned in a renal vein or immediately downstream thereof to create backpressure in the renovascular circulation.
- the blood perfusion modification device may comprise a flow redirector positioned downstream of a renal artery to redirect blood flow to the renal artery.
- the blood perfusion modification device may comprise a pump.
- the pump may be positioned upstream of a renal artery to supplement blood flow to the renal artery or positioned downstream of a renal vein to supplement blood flow from the renal vein.
- the blood perfusion modification device may comprise a drug delivery device.
- the blood perfusion modification device may be positioned intravascularly or extravascularly.
- the blood perfusion modification device may comprise an inflatable cuff, a rotatable ring, a hydraulic piston, a solenoid, an inflatable balloon, or a drug delivery device.
- the control system may include a processor and memory.
- the memory may include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal.
- the algorithm may dictate activation or deactivation control signals depending on the sensor signal or a mathematical derivative thereof.
- the algorithm may dictate an activation or a deactivation control signal when the sensor signal falls below a lower predetermined threshold value, rises above an upper predetermined threshold value or when the sensor signal indicates a specific physiologic event.
- FIG. 1 is a schematic illustration of the renovasculature and associated anatomy
- FIG. 2 is a schematic illustration of a renal vein flow regulator system in accordance with the present invention.
- FIG. 3 is a schematic illustration of a flow redirection system in accordance with the present invention.
- FIG. 4 is a schematic illustration of an arterial flow pump system in accordance with the present invention.
- FIG. 5 is a schematic illustration of a venous flow pump system in accordance with the present invention.
- FIGS. 6A and 6B are side cross sectional schematic illustrations of an extraluminal flow regulator/redirector in the form of an inflatable cuff in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively;
- FIGS. 7A and 7B are side cross sectional schematic illustrations of an intraluminal flow regulator/redirector in the form of an inflatable balloon in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively;
- FIGS. 8A and 8B are side cross sectional schematic illustrations of an extraluminal flow regulator/redirector in the form of a hydraulic piston or solenoid in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively;
- FIGS. 9A and 9B are side cross sectional schematic illustrations of an extraluminal flow regulator/redirector in the form of a rotatable ring in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively;
- FIG. 10 is a side cross sectional schematic illustration of an extraluminal flow supplementor/pump in the form of a series of balloons or solenoids in accordance with the present invention, shown in the deactivated (unconstricted) state;
- FIG. 11 is a side cross sectional schematic illustration of an intraluminal flow supplementor/pump in the form of an impeller in accordance with the present invention.
- FIG. 12 is a side cross sectional schematic illustration of an extraluminal site to specific drug delivery apparatus.
- FIG. 1 is a schematic illustration of the renal system 10 of an adult human.
- the right and left sides of the renal system 10 are substantially symmetrical and are identified by the letters R and L, respectively.
- Blood is supplied to the kidneys 12 by way of the descending aorta 14 and the renal arteries 20 .
- Blood is removed from the kidneys 12 by way of the inferior vena cava 16 and the renal veins 22 .
- the descending aorta 14 bifurcates downstream into the common iliac arteries 28 .
- the direction of the arterial blood flow in the descending aorta 14 is indicated by arrows 24
- the direction of the venous blood flow in the inferior vena cava 16 is indicated by arrows 26 .
- Waste products are removed from the blood by the kidneys 12 and transported to the bladder (not shown) by way of ureters 18 .
- a number of body systems are activated to compensate for the heart's inability to pump sufficient blood or in the presence of renal disease or restricted renal perfusion (e.g., renal artery stenosis causing hypertension and/or renal disease).
- the renal system 10 senses the heart's inability to pump sufficient blood by decreased blood perfusion (flow, pressure, etc.) in the renal arteries 20 and other parts of the renovasculature.
- the renal system 10 responds to this to condition by initiating or contributing to a neurohormonal sequence that signals the heart to increase heart rate and force of contraction to increase the cardiac output, signals the kidneys to expand the blood volume by retaining sodium and water, and it signals the arterioles to constrict to elevate the blood pressure.
- the present invention basically provides a number of devices, systems and methods by which the renal system experiences normal or supranormal perfusion even in the face of reduced cardiac output and/or vasoconstriction.
- the renal system 10 including renal baroreceptors and the juxtaglomerular apparatus are not activated, and the viscous cycle referred to above may be stopped or at least moderated.
- the present invention provides a number of devices, systems and methods by which renal perfusion and pressure can be increased, thereby restoring or augmenting perfusion of the kidney and blood filtration.
- the present invention increases interstitial pressure to reduce sodium and water reabsorption, which have been shown to be interrelated.
- the present invention generally provides a system including a physiologic sensor 30 (e.g., a transducer or a gauge), a blood perfusion modification device 50 , 60 , 70 and/or 80 (e.g., a flow regulator, a flow redirector or a pump), and a control system 40 .
- perfusion, blood perfusion and renal perfusion generally refer to a fluid dynamic property of blood flow such as volumetric flow rate, flow velocity and/or pressure including absolute, mean or pulse pressure, or a fluid static property such as interstitial pressure.
- the sensor 30 senses and/or monitors one or more fluid dynamic properties of blood flow or renal pressure or function and is generically referred to herein as a sensor.
- the blood perfusion modification devices 50 , 60 , 70 , 80 modify one or more fluid dynamic properties of blood flow and are generically referred to herein as modification devices.
- the connections between the components 30 / 40 / 50 / 60 / 70 / 80 may be physical (e.g., wires, tubes, cables, etc.) or remote (e.g., transmitter/receiver, inductive, magnetic, etc.).
- the connection may travel intraarterially, intravenously, intraabdominally, subcutaneously, or through other natural tissue paths.
- the need to preserve or augment renal blood perfusion or pressure may be, for example, detected by the sensor 30 , which may be placed in one or both renal arteries 20 , the descending aorta 14 , or upstream thereof, within the kidney itself or in the urinary bladder.
- the control system 40 generates a control signal as a function of the received sensor signal.
- the control signal activates, deactivates or modifies one or more parameters of the blood perfusion modification device 50 , 60 , 70 , 80 .
- the control system 40 when the sensor 30 detects a reduction in cardiac output, the control system 40 generates an activation control signal to activate the blood perfusion modification device 50 , 60 , 70 , 80 thereby increasing renovascular perfusion such that the renal system 10 does not experience reduced perfusion.
- the control system 40 When the sensor 30 detects improvement or normalization in the sensed parameter, the control system 40 generates a control signal to deactivate or otherwise modify the activity of the blood perfusion modification device 50 , 60 , 70 , 80
- the sensor 30 is operably coupled to the control system 40 by electric sensor cable or lead 32 .
- the sensor 30 may comprise any suitable device that measures a fluid dynamic property of blood flow or other parameters) of interest which is (are) indicative of the need to modify (i.e., increase) renal perfusion.
- the sensor 30 may comprise a transducer or gauge that measures blood pressure (systolic, diastolic, pulse or average pressure), blood volumetric flow rate, blood flow velocity, etc.
- the sensor 30 may comprise a transducer or gauge that measures urine production (e.g., volumetric), composition or concentration, a change in any of which may be indicative of the need to modify renal perfusion.
- transducers or gauges examples include a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, an ultrasonic volumetric flow rate transducer, a thermodilution flow velocity transducer, and a capacitive pressure transducer. Although only one sensor 30 is shown, multiple sensors 30 of the same or different type at the same or different location may be utilized.
- the senor 30 is preferably positioned on the arterial side of the renal vasculature.
- the sensor 30 may be located in or on one or both kidneys 12 , renal arteries 20 , the descending aorta 14 , or upstream thereof, such that suboptimal renal perfusion may be readily ascertained.
- the sensor may alternatively be implanted in the bladder to measure urine production.
- the sensor 30 may be mounted intravascularly or extravascularly, depending on the type of transducer or gauge utilized.
- control system 40 includes a control block 41 comprising a processor 43 and a memory 42 .
- Control system 40 is connected to the sensor 30 by way of sensor cable 32 .
- Control system 40 is also connected to the blood perfusion modification device 50 , 60 , 70 , 80 by way of electric control cable 38 .
- the control system 40 receives a sensor signal (also referred to as a transducer signal) from the sensor 30 by way of sensor cable 32 , and transmits a control signal to the blood perfusion modification device 50 , 60 , 70 , 80 by way of control cable 38 .
- a sensor signal also referred to as a transducer signal
- the memory 42 may contain data related to the sensor signal, the control signal, and/or values and commands provided by the input device 44 .
- the memory 42 may also include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal.
- the algorithm may dictate activation, deactivation or modification control signals depending on the sensor signal or a mathematical derivative thereof. For example, the algorithm may dictate an activation control signal when the sensor signal falls below a lower predetermined threshold value.
- the algorithm may also dictate a deactivation control signal when the sensor signal rises above an upper predetermined uphold threshold value.
- the lower threshold value may be approximately 80 mm Hg and the upper threshold value may be approximately 120 mm Hg. If the sensor signal is indicative of diastolic pressure, the lower threshold value may be approximately 60 mm Hg and the upper threshold value may be approximately 80 mm Hg. If the sensor signal is indicative of mean pressure, the lower threshold value may be approximately 70 mm Hg and the upper threshold value may be approximately 110 mm Hg. If the sensor signal is indicative of flow rate, the lower threshold value may be approximately 500 ml/min and the upper threshold value may be approximately 700 ml/min for each kidney.
- the algorithm dictates activation or deactivation of the blood perfusion modification device 50 , 60 , 70 , 80 to thereby increase or decrease real or apparent renovascular perfusion by instigating a control signal transmission as a function of the sensor signal.
- the control system 40 may operate as a closed loop utilizing feedback from the sensor 30 , or as an open loop utilizing commands received by input device 44 .
- the open loop operation of the control system 40 preferably utilizes some feedback from the sensor 30 , but may also operate without feedback.
- Commands received by the input device 44 may directly influence the control signal or may alter the software and related algorithms contained in memory 42 .
- the patient and/or treating physician may provide commands to input device 44 .
- Display 45 may be used to view the sensor signal and/or the software contained in memory 42 .
- the control signal generated by the control system 40 may be continuous, periodic, episodic or a combination thereof, as dictated by a preset or programmable algorithm contained in memory 42 .
- Continuous control signals include a constant pulse, a constant sequence of pulses, a triggered pulse and a triggered sequence of pulses.
- periodic control signals include each of the continuous control signals described above which have a designated start time (e.g., beginning of each minute, hour or day) and a designated duration (e.g., 1 second, 1 minute, 1 hour).
- Examples of episodic control signals include each of the continuous control signals described above which are triggered by an episode (e.g., activation by the patient/physician, an increase in blood pressure above a certain threshold, ECG, etc).
- the control system 40 may be implanted in whole or in part.
- the entire control system 40 may be carried externally by the patient utilizing transdermal connections to the sensor lead 32 and the control lead 38 .
- the control block 41 may be implanted with the input device 44 and display 45 carried externally by the patient utilizing transdermal connections therebetween.
- the transdermal connections may be replaced by cooperating transmitters/receivers to remotely communicate between components of the control system 40 and/or the sensor 30 and blood perfusion modification device 50 , 60 , 70 , 80 . If all of the components are implanted, the inter component connections may be eliminated.
- FIG. 2 schematically illustrates a renal vein flow regulator 50 in accordance with an embodiment of the present invention.
- the flow regulator 50 may be intravascularly or extravascularly positioned in or on one or both renal veins 22 or downstream thereof on the inferior vena cava 16 .
- Flow regulator 50 may be activated or deactivated by a control signal received from control cable 38 .
- the flow regulator 50 constricts the renal vein 22 or otherwise reduces the cross sectional area of the lumen therein to create back pressure in the renovasculature, thereby increasing blood and interstitial pressure in the renal tissues.
- the renal system 10 does not perceive the reduction in perfusion.
- FIG. 3 schematically illustrates a flow redirector 60 in accordance with another embodiment of the present invention.
- the flow redirector 60 may be intravascularly or extravasculary positioned in or on the descending aorta 14 downstream of the renal arteries 20 , or in or on one or both of the common iliac arteries 28 .
- the flow redirector 60 may be activated or deactivated by a control signal received from control cable 38 . When activated, the flow redirector 60 constricts the descending aorta or otherwise reduces the size of the lumen therein to redirect flow to the renal arteries 20 thereby increasing renovascular perfusion.
- the flow redirector 60 would be activated in such a manner as to minimize the effects on downstream perfusion into the lower extremities.
- FIG. 4 schematically illustrates an arterial blood flow pump 70 in accordance with another embodiment of the present invention.
- the arterial flow pump 70 may be positioned intravascularly or extravascularly in or on the descending aorta 14 upstream of the renal arteries 20 or in the renal arteries 20 .
- the arterial flow pump 70 may be activated and deactivated by a control signal received from control cable 38 . When activated, the arterial flow pump 70 supplements arterial blood flow to the renal arteries 20 thereby increasing renal perfusion.
- FIG. 5 schematically illustrates a venous blood flow pump 80 in accordance with another embodiment of the present invention.
- Venous flow pump 80 may be intravascularly or extravascularly may be positioned in or on the renal veins 22 , or in or on the inferior vena cava 16 downstream of the renal veins 22 .
- the venous flow pump 80 may be activated and deactivated by a control signal received from control cable 38 . When activated, the venous flow pump 80 reduces blood flow or causes back flow in the renal veins 22 thereby increasing renal back pressure.
- FIGS. 6 12 illustrate various embodiments of flow regulators, flow redirectors and pumps that may be utilized for the blood perfusion to modification devices 50 , 60 , 70 , 80 described with reference to FIGS. 2 5 .
- FIGS. 6 12 schematically illustrate intravascular or extravascular devices disposed in or on a generic vessel 90 having a vascular wall 92 and a vascular lumen 94 .
- the vessel 90 generically refers to the portion of the vasculature in or on which the blood perfusion modification device 50 , 60 , 70 , 80 is positioned as described previously.
- FIGS. 6 12 are longitudinal cross sectional views unless otherwise specified and are generally circular in lateral cross section unless otherwise specified.
- FIGS. 6A and 6B show side cross sectional schematic illustrations of an external inflatable cuff 100 in accordance with an embodiment of the present invention.
- FIG. 6A illustrates the inflatable cuff 100 in the deactivated (unconstricted) state
- FIG. 6B illustrates the inflatable cuff 100 in the activated (constricted) state.
- the inflatable cuff 100 may be used for the renal vein flow regulator 50 illustrated in FIG. 2 or the flow redirector 60 illustrated in FIG. 3 .
- the inflatable cuff 100 illustrated is merely schematic and is intended to generically refer to a wide variety of inflatable cuffs. Examples of inflatable cuffs that may be adapted for use in the present invention are disclosed in U.S. Pat. No. 4,256,094 to Kapp et al. and U.S. Pat. No. 4,881,939 to Newman, the entire disclosures of which are hereby incorporated by reference.
- Inflatable cuff 100 includes a housing 102 which may be connected to the vessel wall 92 utilizing conventional techniques such as sutures 104 .
- Housing 102 contains an inflatable annular balloon 106 having an interior 107 which is in fluid communication with a fluid line 108 .
- the balloon 106 may be an annular geometry with a central passageway to accommodate the vessel 90 therein as illustrated, or may be a geometry without a passageway and reside on one side of the vessel 90 .
- one balloon 106 may be utilized as shown, or a plurality of balloons 106 may be utilized.
- a pressure/vacuum source 110 selectively inflates and deflates the balloon 106 by way of pressure line 108 .
- the pressure/vacuum source 110 is preferably implanted, but may be carried externally by the patient with a transdermal connection to the pressure line 108 .
- a saline liquid inflation fluid is preferred, but other fluids (i.e. liquids and gases) may be used.
- the pressure/vacuum source 110 is connected to the control cable 38 , which provides a control signal from control system 40 to activate or deactivate the pressure/vacuum source 110 and thereby inflate or deflate the balloon 106 .
- the pressure/vacuum source 110 applies pressure and causes the balloon 106 to inflate thereby constricting the vascular wall 92 and obstructing or reducing the size of the internal lumen 94 .
- the internal lumen 94 may be partially or totally occluded by controlling the degree of balloon 106 inflation.
- the pressure/vacuum source 110 applies vacuum and causes the balloon 106 to deflate thereby permitting the vascular wall 92 to return to its unconstricted state and restoring the nominal size of the internal lumen 94 .
- the pressure/vacuum source 110 may be automatically actuated by the control system 40 as discussed above, or may be manually actuated.
- An example of an externally manually actuated pressure/vacuum source is disclosed in U.S. Pat. No. 4,709,690 to Haber, the entire disclosure of which is hereby incorporated by reference.
- Examples of transdermally manually actuated pressure/vacuum sources are disclosed in U.S. Pat. No. 4,586,501 to Claracq, U.S. Pat. No. 4,828,544 to Lane et al., and U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosures of which are hereby incorporated by reference.
- the senor 30 detects a reduction in renal perfusion or other change indicative of the need to activate the system as indicated by a sensor signal transmitted by way of sensor cable 32 to the control system 40 .
- the control system 40 transmits a control signal as a function the sensor signal as dictated by the algorithm contained in memory 42 .
- the control signal is transmitted by way of control cable 38 to the pressure/vacuum source 110 .
- the pressurized fluid source 110 is activated (pressure) or deactivated (vacuum) to inflate or deflate the balloon 106 .
- the reduced size of the vascular lumen 94 causes back pressure in the renal veins 22 and ultimately the renal parenchyma and arterial circulation thereby causing an apparent increase in renovascular perfusion and pressure. If the inflatable cuff 100 is utilized as a flow redirector 60 as illustrated in FIG. 3 , the reduced size of the vascular lumen 94 causes blood to be redirected into the renal arteries 20 thereby causing an increase in renovascular perfusion. In either instance, renovascular perfusion and/or intrarenal pressure are maintained or augmented.
- Inflatable cuff 100 is one example of many different mechanisms for applying external compression to the vascular wall 92 to reduce the size of the internal lumen 94 .
- Other mechanisms for applying for external compression to the vascular wall 92 are described in greater detail with reference to FIGS. 8A , 8 B, 9 A and 9 B.
- external compression may be applied utilizing an electromagnetically actuated ferro fluid device as disclosed in the U.S. Pat. No. 5,509,888 to Miller, the entire disclosure of which is hereby incorporated by reference.
- Another example of an electromagnetically actuated ferro fluid type external compression device is disclosed in U.S. Pat. No. 4,053,952 to Goldstein, the entire disclosure of which is incorporated by reference.
- FIGS. 7A and 7B show cross sectional schematic illustrations of an internal inflatable balloon device 200 in accordance with another embodiment of the present invention.
- FIG. 7A illustrates the inflatable balloon device 200 in the deactivated (unconstricted) state
- FIG. 7B illustrates the inflatable balloon device 200 in the activated (constricted) state.
- the inflatable balloon device 200 may be used for the renal vein flow regulator 50 illustrated in FIG. 2 or the flow redirector 60 illustrated in FIG. 3 .
- the internal inflatable balloon device 200 is merely schematic and is intended to generically refer to a wide variety of internal occlusion devices.
- An example of an internal inflatable balloon device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 4,682,583 to Burton et al., the entire disclosure of which is hereby incorporated by reference.
- Another example of an internal inflatable balloon device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosure of which is hereby incorporated by reference.
- Inflatable balloon device 200 includes a housing 202 which may be connected to the inside surface of the vessel wall 92 utilizing conventional techniques such as those used for implanting vascular stents, grafts and filters.
- Housing 202 includes an inflatable annular balloon 206 having an interior 207 which is in fluid communication with a fluid line 208 .
- the balloon 206 may be an annular geometry with a central perfusion passageway as illustrated, or may be a geometry without a passageway and reside on one side of the vessel 90 .
- one balloon 206 may be utilized as shown, or a plurality of balloons 206 may be used.
- a pressure/vacuum source 110 selectively inflates and deflates the balloon 206 by way of pressure line 208 .
- the pressure/vacuum source 110 is connected to the control cable 38 , which provides a control signal from control system 40 to activate or deactivate the pressure/vacuum source 110 and thereby inflate or deflate the balloon 206 .
- the pressure/vacuum source 110 applies pressure and causes the balloon 206 to inflate thereby obstructing or reducing the size of the internal lumen 94 .
- the internal lumen 94 may be partially or totally occluded by adjusting the degree of balloon 206 inflation.
- the internal inflatable balloon device 200 basically operates on the same principles as the external compression device 100 described previously, except that inflatable balloon device 200 does not utilize external compression, but rather totally or partially occludes the vascular lumen 94 without affecting the vascular wall 92 .
- FIGS. 8A and 8B show side cross sectional schematic illustrations of a piston device 300 in accordance with another embodiment of the present invention.
- FIG. 8A illustrates the piston device 300 in the deactivated (unconstricted) state
- FIG. 8B illustrates the piston device 300 in the activated (constricted) state.
- the piston device 300 may be used for the renal vein flow regulator 50 illustrated in FIG. 2 or the flow redirector 60 illustrated in FIG. 3 .
- the piston device 300 illustrated is merely schematic and is intended to generically refer to a wide variety of piston type devices.
- An example of a piston type device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 4,014,318 to Dockum et al., the entire disclosure of which is hereby incorporated by reference.
- Piston device 300 includes a housing 302 which may be connected to the vessel wall 92 utilizing conventional techniques such as sutures 304 .
- Housing 302 includes an internal chamber 307 in which piston 306 is slidably disposed.
- the internal chamber 307 is in fluid communication with a fluid line 308 .
- a pressure/vacuum source 110 selectively fills an empties the chamber 307 by way of pressure line 308 .
- the pressure/vacuum source 110 is connected to the control cable 38 , which provides a control signal from control system 40 to activate or deactivate the pressure/vacuum source 110 .
- the pressure/vacuum source 110 When activated, the pressure/vacuum source 110 fills the internal chamber 307 with fluid thereby displacing the piston 306 to constrict the vascular wall 92 and reduce the size of the internal lumen 94 .
- the internal lumen 94 may be partially or totally occluded by adjusting the displacement distance of the piston 306 .
- the pressure/vacuum source 110 empties the internal chamber 307 causing the piston 306 to be displaced back into the chamber 307 thereby permitting the vascular wall 92 to return to its unconstricted state and restoring the nominal size of the internal lumen 94 .
- the function and use of the piston device 300 is otherwise essentially the same as the other external compression device 100 discussed previously.
- the piston device 300 operates by hydraulic actuation.
- the piston device 300 may operate by electromagnetic actuation such as provided by a solenoid device.
- electromagnetic solenoid device An example of an electromagnetic solenoid device is disclosed in Dockum et al. '318 mentioned previously. If electromagnetic actuation is utilized, the pressure/vacuum source 110 may be replaced by a suitable amplifier to power the electromagnets in the solenoid.
- the function and use of the solenoid alternative is otherwise essentially the same as the hydraulic embodiment discussed above.
- FIGS. 9A and 9B show side cross sectional schematic illustrations of a rotatable ring device 400 in accordance with another embodiment of the present invention.
- FIG. 9A illustrates the rotatable ring device 400 in the deactivated (unconstricted) state
- FIG. 9B illustrates the rotatable ring device 400 in the activated (constricted) state.
- the rotatable ring device 400 may be used for the renal vein flow regulator 50 illustrated in FIG. 2 or the flow redirector 60 illustrated in FIG. 3 .
- the rotatable ring device 400 is merely schematic and is intended to generically refer to a wide variety of rotatable ring devices.
- An example of a rotatable ring device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 4,551,862 to Haber, the entire disclosure of which is hereby incorporated by reference.
- Rotatable ring device 400 includes a housing 402 which may be connected to the vessel wall 92 utilizing conventional techniques such as sutures 404 .
- Housing 402 includes one or more rings 406 which are operably connected to a linear actuation cable 408 to cause rotation of the ring or rings 406 substantially as described in Haber '862.
- the linear actuation cable 408 is connected to a solenoid device 410 which selectively pushes or pulls the linear actuation cable 408 to cause clockwise or counter clockwise rotation of the rotatable rings 406 .
- the solenoid device 410 is connected to the control cable 38 which provides a control signal from the control system 40 to activate or deactivate the solenoid device 410 and thereby rotate the rings 406 .
- the solenoid 410 When activated, the solenoid 410 causes the rotatable rings 406 to constrict the vascular wall 92 and reduce the size of the lumen 94 .
- the internal lumen 94 may be partially or totally occluded by adjusting the degree of rotation of the rings 406 .
- the solenoid device 410 causes the rotatable rings to unconstrict thereby permitting the vascular wall 92 to return to its unconstricted state and restoring the nominal size of the internal lumen 94 .
- the function and use of the rotatable ring device 400 is otherwise substantially the same as the other external compression devices 100 , 300 discussed previously.
- FIG. 10 shows a side cross sectional schematic illustration of an external pump 500 in accordance with an embodiment of the present invention.
- the external pump 500 may be used for the arterial flow pump 70 illustrated in FIG. 4 or the venous flow pump 80 in FIG. 5 .
- the external pump 500 is merely schematic and is intended to generically refer to a wide variety of extraluminal vascular pumps.
- An example of an extraluminal vascular pump that may be adapted for use in the present invention is disclosed in Dockum et al. '318 mentioned previously.
- Extraluminal pump 500 includes a housing 502 which may be connected to the vessel wall 92 utilizing conventional techniques such as sutures 504 .
- Housing 502 includes a plurality of inflatable balloons 506 each having an interior 507 which is in fluid communication with a plurality of fluid lines 508 . Fluid communication to each of the balloons 506 is maintained by separate lumens within the fluid line 508 such that the balloons 506 may be inflated independently.
- a pressure/vacuum source 110 is fluidly connected to a manifold 510 which sequentially inflates and deflates each of the balloons 506 to cause a sequence of constrictions about the vessel wall 92 , thereby creating a pumping action within the vascular lumen 94 .
- the direction and speed of the inflation sequence may be modified to change the pumping direction and flow rate.
- the pressure/vacuum source 110 is connected to the control cable 38 which provides a control signal from the control system 40 to activate and deactivate the pressure/vacuum source 110 and manifold 510 . When activated, the pressure/vacuum source 110 and manifold 510 cause the balloons 506 to sequentially inflate thereby producing the pumping action.
- the pressure/vacuum source 110 applies a vacuum to deflate the balloons 506 .
- the pressure/vacuum source 110 and manifold 510 may be reactivated to initiate another pumping cycle. If no further pumping action is desired, the pressure/vacuum source 110 maintains a vacuum such that the balloons 506 remain deflated.
- the external pump 500 selectively supplements arterial blood flow and/or perfusion pressure to the renal arteries 200 thereby increasing renal perfusion. If the external pump 500 is utilized for the venous flow pump 80 illustrated in FIG. 5 , the external pump 500 reduces blood flow or causes back flow in the renal veins 22 thereby increasing renal back pressure. In either instance, the renovascular perfusion and/or intrarenal pressure are maintained or augmented.
- the external pump 500 may utilize hydraulically actuated balloons 506 as illustrated and described, or may utilize hydraulically actuated pistons similar to the embodiment described with reference to FIGS. 8A and 8B .
- the pistons may be electromagnetically actuated as with a solenoid type device as described in Dockum et al. '318 and as described with reference to the alternative embodiment of FIGS. 8A and 8B .
- the external pump 500 may be hydraulically actuated by utilizing balloons 506 , or may be hydraulically or electromagnetically actuated by replacing the balloons 506 with pistons slidably disposed in chambers.
- FIG. 11 shows a side cross sectional schematic illustration of an internal pump 600 in accordance with an embodiment of the present invention.
- FIG. 11 illustrates the intraluminal pump 600 in the static or deactivated state.
- the intraluminal pump 600 may be utilized for the arterial flow pump 70 illustrated in FIG. 4 or the venous flow pump 80 illustrated in FIG. 5 .
- the intraluminal pump 600 is merely schematic and is intended to generically wide variety of intraluminal vascular pumps.
- An example of an intraluminal vascular pump suitable for use in the present invention is disclosed in U.S. Pat. No. 5,692,882 to Bozeman, Jr. et al., the entire disclosure of which is hereby incorporated by reference.
- the intraluminal pump 600 includes a housing 602 which may be connected to the vessel wall 92 utilizing the same anchoring techniques used by intravascular stents, to grafts and filters.
- Housing 602 includes proximal and distal struts 603 which support rotatable axle 604 .
- One or more impeller blades 605 are rigidly connected to the axle 604 and rotate relative to the housing 602 and struts 603 . When the impeller blades 605 are rotated, blood in the vascular lumen 94 is biased in the proximal or distal direction.
- Impeller blades 605 may be formed of a ferrous material suitable for forming into permanent magnets. Alternatively, the impeller blades 605 may be formed of a nonferrous material but include a ferrous material disposed thereon for forming into permanent magnets.
- the housing 602 includes a plurality of electrical windings 606 which may be selectively activated by electrical cable 608 .
- Electrical cable 608 is connected to power amplifier 610 which may be selectively activated or deactivated by the control system 40 by way of control cable 38 .
- power amplifier 610 By activating the power amplifier 610 , electrical power is supplied to the coil windings 606 in the housing 602 .
- the coil windings 606 generate a magnetic field causing the permanent magnets disposed on the impeller blade 605 to be displaced.
- Multiple coil windings 606 may be utilized about the periphery of the housing 602 to sequentially activate and deactivate magnetic fields causing rotation of the impeller blades 605 .
- the direction and frequency of the sequential activation may be modified to change the direction and speed of rotation, and thus the direction and degree of pumping action.
- supplemental fluid may be supplied to the pump 600 by connection to a source of blood within the body or by connection to a fluid reservoir containing a suitable fluid such as saline.
- the function and use of internal pump 600 is otherwise essentially the same as external pump 500 .
- Delivery device 700 includes a housing 702 which may be connected the vessel wall 92 utilizing conventional techniques such as sutures 705 .
- Housing 702 includes an annular recess 705 which is in fluid communication with a fluid delivery line 708 .
- Annular recess 705 is open to the exterior of the vascular wall 92 .
- Housing 702 includes annular seals 706 disposed proximally and distally of the annular recess 705 to create a fluid tight seal between the housing 702 and the vascular wall 92 .
- annular seals 706 maintain fluid in the annular recess 705 .
- fluid delivered to the annular recess 705 via fluid delivery lines 708 remains in intimate contact with the exterior of the vascular wall 92 at the desired location.
- Fluid line 708 is connected to a fluid delivery pump/reservoir 710 which is connected to the control cable 38 .
- the control cable 38 provides a control signal from the control system 40 to activate or deactivate the pump/reservoir 710 .
- fluid contained in the reservoir 710 is delivered to the annular recess 705 by way of fluid line 708 .
- the fluid contained in the reservoir 710 is preferably a vasoconstrictor such as phenylephrine.
- the reservoir may contain a vasodilator such as hydralazine or nitroprusside.
- the vasoconstrictor when the pump/reservoir 710 is activated, the vasoconstrictor is delivered to the annular recess 705 thereby constricting the vascular wall 92 and obstructing or reducing the size of the internal lumen 94 .
- Internal lumen 94 may be partially or totally closed by varying the amount and strength of the vasoconstrictor.
- the pump/reservoir 710 When deactivated, the pump/reservoir 710 may deliver a dilution fluid or a vasodilator to reduce or reverse the effects of the vasoconstrictor, thereby permitting or causing the vascular wall 92 to return to its unconstricted state and restoring the nominal size of the internal lumen 94 .
- the function and use of the vasoconstrictor delivery device 700 is otherwise substantially the same as the external compression devices 100 , 300 described previously.
- the present invention provides a number of devices 100 , 200 , 300 , 400 , 500 , 600 , 700 and systems 30 , 40 , 50 , 60 , 70 , 80 and methods by which the real or apparent renovasculature perfusion and intrarenal pressure may be selectively and controllably increased.
- the present invention reduces or reverses neurohormonal activation and fluid retention, and thereby minimizes their deleterious effects on the heart, vasculature, kidneys and other body systems.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
Abstract
Devices, systems and methods by which the real or apparent renovascular perfusion and intrarenal pressure may be selectively and controllably increased. By selectively and controllably increasing renovascular perfusion and interstitial hydrostatic pressure when the heart is unable to pump sufficient blood or when renal perfusion is suboptimal, the present invention reduces or reverses neurohormonal activation and fluid retention, and thereby minimizes their deleterious effects on the heart, vasculature, kidneys and other body systems.
Description
- The present application is a continuation of U.S. patent application Ser. No. 10/453,678, filed Jun. 2, 2003, which is a divisional of U.S. patent application Ser. No. 09/702,089, filed Oct. 30, 2000, the full disclosure of which is incorporated herein by reference.
- The present invention generally relates to medical devices and methods of use for the treatment and/or management of cardiovascular and renal disorders. Specifically, the present invention relates to devices and methods for controlling renal perfusion in the renovascular system for the treatment and/or management of cardiovascular disorders such as hypertension and congestive heart failure, and renal disorders such as renal insufficiency and end stage renal disease.
- Cardiovascular disease is a major contributor to patient illness and mortality. It also is a primary driver of health care expenditure, costing more than $326 billion each year in the United States. Hypertension, or high blood pressure, is a major cardiovascular disorder that is estimated to affect over 50 million people in the United States alone. Of those with hypertension, it is reported that fewer than 30% have their blood pressure under control. Hypertension is a leading cause of heart failure and stroke. It is the primary cause of death in over 42,000 patients per year and is listed as a primary or contributing cause of death in over 200,000 patients per year in the U.S. Accordingly, hypertension is a serious health problem demanding significant research and development for the treatment thereof.
- Hypertension occurs when the body's smaller blood vessels (arterioles) constrict, causing an increase in blood pressure. Because the blood vessels constrict, the heart must work harder to maintain blood flow at the higher pressures. Although the body may tolerate short periods of increased blood pressure, sustained hypertension may eventually result in damage to multiple body organs, including the kidneys, brain, eyes and other tissues, causing a variety of maladies associated therewith. The elevated blood pressure may also damage the lining of the blood vessels, accelerating the process of atherosclerosis and increasing the likelihood that a blood clot may develop. This could lead to a heart attack and/or stroke. Sustained high blood pressure may eventually result in an enlarged and damaged heart (hypertrophy), which may lead to heart failure.
- Heart failure is the final common expression of a variety of cardiovascular disorders, including ischemic heart disease. It is characterized by an inability of the heart to pump enough blood to meet the body's needs and results in fatigue, reduced exercise capacity and poor survival. It is estimated that approximately 5,000,000 people in the United States suffer from heart failure, directly leading to 39,000 deaths per year and contributing to another 225,000 deaths per year. It is also estimated that greater than 400,000 new cases of heart failure are diagnosed each year. Heart failure accounts for over 900,000 hospital admissions annually, and it is the most common discharge diagnosis in patients over the age of 65 years. It has been reported that the cost of treating heart failure in the United States exceeds $20 billion annually. Accordingly, heart failure is also a serious health problem demanding significant research and development for the treatment and/or management thereof.
- End stage renal disease (ESRD) affects over 300,000 people in the United States, with an annual incidence of over 79,000. Death from ESRD occurred in over 60,000 cases in 1998; the five year survival rate is less than 30%. Medicare payments in 1998 for the treatment of ESRD exceeded $10 billion. Accordingly, ESRD is a major health problem demanding improved therapy and management.
- Heart failure results in the activation of a number of body systems to compensate for the heart's inability to pump sufficient blood. Many of these responses are mediated by an increase in the level of activation of the sympathetic nervous system as well as activation of multiple other neurohormonal responses. Generally speaking, this sympathetic nervous system activation signals the heart to increase heart rate and force of contraction to increase the cardiac output; it signals the kidneys to expand the blood volume by retaining sodium and water; and it signals the arterioles to constrict to elevate to the blood pressure. The cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state. Accordingly, it is desirable to reduce the level of sympathetic nervous system and other neurohormonal activation in order to stop or at least minimize this vicious cycle and thereby treat or manage the heart failure.
- A number of drug treatments have been proposed for the management of hypertension, heart failure and other cardiovascular and renal disorders. These include vasodilators to reduce the blood pressure and ease the workload of the heart, diuretics to reduce fluid overload, inhibitors and blocking agents of the body's neurohormonal responses, and other medicaments.
- Various surgical procedures have also been proposed for these maladies. For example, heart transplantation has been proposed for patients who suffer from severe, refractory heart failure. Alternatively, an implantable medical device such as a ventricular assist device may be implanted in the chest to increase the pumping action of the heart. Alternatively, an intra aortic balloon pump may be used for maintaining heart function for short periods of time, but typically no longer than one month. Other surgical procedures are available as well.
- Although each of these alternative approaches is beneficial in some ways, each of the therapies has its own disadvantages. For example, drug therapy is often incompletely effective. Some patients may be unresponsive (refractory) to medical therapy. Drugs often have unwanted side effects and may need to be given in complex regimens. These and other factors contribute to poor patient compliance with medical therapy. Drug therapy may also be expensive, adding to the health care costs associated with these disorders. Likewise, surgical approaches are very costly, may be associated with significant patient morbidity and mortality and may not alter the natural history of the disease. Accordingly, there continues to be a substantial and long felt need for new devices and methods for treating and/or managing high blood pressure, heart failure and renal disease, as well as their associated complications.
- The present invention provides a number of devices, systems and methods by which the real or apparent renovascular perfusion and the renal interstitial hydrostatic pressure may be selectively and controllably increased. By selectively and controllably increasing renovascular perfusion and interstitial hydrostatic pressure when the heart is unable to pump sufficient blood or when renal perfusion is otherwise suboptimal, the renal system does not experience the reduced perfusion. Because the renal system does not experience the reduced perfusion, it does not initiate or contribute to, and may reduce the neurohormonal activation normally caused by reduced cardiac output and suboptimal renal perfusion, nor does it begin or continue, and could reverse the process of sodium and water retention that also would otherwise result. Thus, by selectively and controllably increasing renovascular perfusion during periods of decreased cardiac output or suboptimal renal perfusion, the present invention reduces or reverses neurohormonal activation and fluid retention, and thereby minimizes their deleterious effects on the heart, vasculature, kidneys and other body systems.
- In the case of end stage renal disease (ESRD), the present invention provides a number of devices, systems and methods by which renal perfusion and pressure can be increased, thereby restoring or augmenting perfusion of the kidney and blood filtration. In addition, by increasing renal perfusion, the present invention increases interstitial pressure to reduce sodium and water reabsorption, which have been shown to be interrelated.
- In an exemplary embodiment, the present invention provides a method of treating a patient utilizing a blood perfusion modification device, one or more physiologic sensors, and a control system. The blood perfusion modification device may be positioned in the renovascular circulation or immediately adjacent thereto. The sensor is preferably positioned in a renal artery or upstream thereof, but may also be placed in, on or adjacent the patient to generate a signal indicative of the need to modify renal perfusion. For example, the sensor may be positioned in a kidney, a renal artery or vein or adjacent thereto to generate a signal indicative of arterial blood perfusion, renal venous pressure or renal interstitial pressure. The blood perfusion modification device may be activated, deactivated or otherwise modified as a function of the sensor signal to cause or simulate a change, and preferably an increase, in renal perfusion and/or pressure. This method may be used to treat a number of clinical conditions including congestive heart failure, hypertension, renal failure, cardiovascular abnormalities, and the like. In each instance, the method may include the initial step of diagnosing or monitoring the clinical condition or a symptom or sign thereof, and thereafter providing treatment as needed.
- The present invention also provides a system including a blood perfusion modification device (e.g., a flow regulator, a flow redirector or a pump), a physiologic sensor (e.g., a transducer or a gauge), and a control system operably connected to both. The blood perfusion modification device is preferably positioned in the renovascular circulation. The control system (or a portion thereof) may be implanted or carried externally by the patient. In the closed loop mode, the sensor generates a sensor signal indicative of the need to modify renovascular perfusion, and the control system generates a control signal to activate the modification device as a function of the sensor signal to thereby modify the renovascular circulation. In the open loop mode, which may or may not utilize feedback from the sensor, the control system generates a control signal to activate the modification device as dictated by, for example, a pre programmed algorithm, the patient or the physician.
- The sensor may comprise, for example, a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, a thermodilution flow transducer, or a strain gauge. As such, the sensor may generate a signal indicative of pressure (e.g., mean, systolic, diastolic or pulse), blood flow velocity, vasoactivity, or other fluid dynamic property. Alternatively, the sensor may measure the blood concentration of a component (e.g., sodium, renin, etc.) or an arterial/venous difference in concentration of the component.
- The blood perfusion modification device may comprise a flow regulator positioned in a renal vein or immediately downstream thereof to create backpressure in the renovascular circulation. Alternatively, the blood perfusion modification device may comprise a flow redirector positioned downstream of a renal artery to redirect blood flow to the renal artery. As a further alternative, the blood perfusion modification device may comprise a pump. The pump may be positioned upstream of a renal artery to supplement blood flow to the renal artery or positioned downstream of a renal vein to supplement blood flow from the renal vein. As yet a further alternative, the blood perfusion modification device may comprise a drug delivery device. In each of these embodiments, the blood perfusion modification device may be positioned intravascularly or extravascularly. By way of example, not limitation, the blood perfusion modification device may comprise an inflatable cuff, a rotatable ring, a hydraulic piston, a solenoid, an inflatable balloon, or a drug delivery device.
- The control system may include a processor and memory. The memory may include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal. The algorithm may dictate activation or deactivation control signals depending on the sensor signal or a mathematical derivative thereof. The algorithm may dictate an activation or a deactivation control signal when the sensor signal falls below a lower predetermined threshold value, rises above an upper predetermined threshold value or when the sensor signal indicates a specific physiologic event.
-
FIG. 1 is a schematic illustration of the renovasculature and associated anatomy; -
FIG. 2 is a schematic illustration of a renal vein flow regulator system in accordance with the present invention; -
FIG. 3 is a schematic illustration of a flow redirection system in accordance with the present invention; -
FIG. 4 is a schematic illustration of an arterial flow pump system in accordance with the present invention; -
FIG. 5 is a schematic illustration of a venous flow pump system in accordance with the present invention; -
FIGS. 6A and 6B are side cross sectional schematic illustrations of an extraluminal flow regulator/redirector in the form of an inflatable cuff in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively; -
FIGS. 7A and 7B are side cross sectional schematic illustrations of an intraluminal flow regulator/redirector in the form of an inflatable balloon in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively; -
FIGS. 8A and 8B are side cross sectional schematic illustrations of an extraluminal flow regulator/redirector in the form of a hydraulic piston or solenoid in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively; -
FIGS. 9A and 9B are side cross sectional schematic illustrations of an extraluminal flow regulator/redirector in the form of a rotatable ring in accordance with the present invention, shown in the deactivated (unconstricted) and activated (constricted) states, respectively; -
FIG. 10 is a side cross sectional schematic illustration of an extraluminal flow supplementor/pump in the form of a series of balloons or solenoids in accordance with the present invention, shown in the deactivated (unconstricted) state; -
FIG. 11 is a side cross sectional schematic illustration of an intraluminal flow supplementor/pump in the form of an impeller in accordance with the present invention; and -
FIG. 12 is a side cross sectional schematic illustration of an extraluminal site to specific drug delivery apparatus. - The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
- Refer now to
FIG. 1 which is a schematic illustration of therenal system 10 of an adult human. The right and left sides of therenal system 10 are substantially symmetrical and are identified by the letters R and L, respectively. Blood is supplied to the kidneys 12 by way of the descendingaorta 14 and the renal arteries 20. Blood is removed from the kidneys 12 by way of theinferior vena cava 16 and the renal veins 22. - The descending
aorta 14 bifurcates downstream into the common iliac arteries 28. The direction of the arterial blood flow in the descendingaorta 14 is indicated byarrows 24, and the direction of the venous blood flow in theinferior vena cava 16 is indicated byarrows 26. Waste products are removed from the blood by the kidneys 12 and transported to the bladder (not shown) by way of ureters 18. - As stated previously, a number of body systems are activated to compensate for the heart's inability to pump sufficient blood or in the presence of renal disease or restricted renal perfusion (e.g., renal artery stenosis causing hypertension and/or renal disease). In the case of heart failure, the
renal system 10 senses the heart's inability to pump sufficient blood by decreased blood perfusion (flow, pressure, etc.) in the renal arteries 20 and other parts of the renovasculature. Therenal system 10 responds to this to condition by initiating or contributing to a neurohormonal sequence that signals the heart to increase heart rate and force of contraction to increase the cardiac output, signals the kidneys to expand the blood volume by retaining sodium and water, and it signals the arterioles to constrict to elevate the blood pressure. The cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state. To address this problem, the present invention basically provides a number of devices, systems and methods by which the renal system experiences normal or supranormal perfusion even in the face of reduced cardiac output and/or vasoconstriction. By maintaining or augmenting renal perfusion, therenal system 10 including renal baroreceptors and the juxtaglomerular apparatus are not activated, and the viscous cycle referred to above may be stopped or at least moderated. - In the case of end stage renal disease (ESRD), the kidney has often undergone substantial scarring and fibrosis. Thus, perfusion of the kidney and filtration of the blood are limited. The present invention provides a number of devices, systems and methods by which renal perfusion and pressure can be increased, thereby restoring or augmenting perfusion of the kidney and blood filtration. In addition, by increasing renal perfusion, the present invention increases interstitial pressure to reduce sodium and water reabsorption, which have been shown to be interrelated.
- With reference to
FIGS. 2 5, the present invention generally provides a system including a physiologic sensor 30 (e.g., a transducer or a gauge), a bloodperfusion modification device control system 40. As used herein, perfusion, blood perfusion and renal perfusion generally refer to a fluid dynamic property of blood flow such as volumetric flow rate, flow velocity and/or pressure including absolute, mean or pulse pressure, or a fluid static property such as interstitial pressure. Thesensor 30 senses and/or monitors one or more fluid dynamic properties of blood flow or renal pressure or function and is generically referred to herein as a sensor. Similarly, the bloodperfusion modification devices components 30/40/50/60/70/80 may be physical (e.g., wires, tubes, cables, etc.) or remote (e.g., transmitter/receiver, inductive, magnetic, etc.). For physical connections, the connection may travel intraarterially, intravenously, intraabdominally, subcutaneously, or through other natural tissue paths. - The need to preserve or augment renal blood perfusion or pressure may be, for example, detected by the
sensor 30, which may be placed in one or both renal arteries 20, the descendingaorta 14, or upstream thereof, within the kidney itself or in the urinary bladder. Thecontrol system 40 generates a control signal as a function of the received sensor signal. The control signal activates, deactivates or modifies one or more parameters of the bloodperfusion modification device sensor 30 detects a reduction in cardiac output, thecontrol system 40 generates an activation control signal to activate the bloodperfusion modification device renal system 10 does not experience reduced perfusion. When thesensor 30 detects improvement or normalization in the sensed parameter, thecontrol system 40 generates a control signal to deactivate or otherwise modify the activity of the bloodperfusion modification device - With continued reference to
FIGS. 2 5, thesensor 30 is operably coupled to thecontrol system 40 by electric sensor cable or lead 32. Thesensor 30 may comprise any suitable device that measures a fluid dynamic property of blood flow or other parameters) of interest which is (are) indicative of the need to modify (i.e., increase) renal perfusion. For example, thesensor 30 may comprise a transducer or gauge that measures blood pressure (systolic, diastolic, pulse or average pressure), blood volumetric flow rate, blood flow velocity, etc. Alternatively, thesensor 30 may comprise a transducer or gauge that measures urine production (e.g., volumetric), composition or concentration, a change in any of which may be indicative of the need to modify renal perfusion. Examples of suitable transducers or gauges for thesensor 30 include a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, an ultrasonic volumetric flow rate transducer, a thermodilution flow velocity transducer, and a capacitive pressure transducer. Although only onesensor 30 is shown,multiple sensors 30 of the same or different type at the same or different location may be utilized. - In this embodiment, the
sensor 30 is preferably positioned on the arterial side of the renal vasculature. In particular, thesensor 30 may be located in or on one or both kidneys 12, renal arteries 20, the descendingaorta 14, or upstream thereof, such that suboptimal renal perfusion may be readily ascertained. The sensor may alternatively be implanted in the bladder to measure urine production. Thesensor 30 may be mounted intravascularly or extravascularly, depending on the type of transducer or gauge utilized. - With continued reference to
FIGS. 2 5,control system 40 includes acontrol block 41 comprising aprocessor 43 and amemory 42.Control system 40 is connected to thesensor 30 by way ofsensor cable 32.Control system 40 is also connected to the bloodperfusion modification device electric control cable 38. Thus, thecontrol system 40 receives a sensor signal (also referred to as a transducer signal) from thesensor 30 by way ofsensor cable 32, and transmits a control signal to the bloodperfusion modification device control cable 38. - The
memory 42 may contain data related to the sensor signal, the control signal, and/or values and commands provided by theinput device 44. Thememory 42 may also include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal. The algorithm may dictate activation, deactivation or modification control signals depending on the sensor signal or a mathematical derivative thereof. For example, the algorithm may dictate an activation control signal when the sensor signal falls below a lower predetermined threshold value. The algorithm may also dictate a deactivation control signal when the sensor signal rises above an upper predetermined uphold threshold value. - The following predetermined threshold values are provided by way of example, not limitation. If the sensor signal is indicative of systolic pressure, the lower threshold value may be approximately 80 mm Hg and the upper threshold value may be approximately 120 mm Hg. If the sensor signal is indicative of diastolic pressure, the lower threshold value may be approximately 60 mm Hg and the upper threshold value may be approximately 80 mm Hg. If the sensor signal is indicative of mean pressure, the lower threshold value may be approximately 70 mm Hg and the upper threshold value may be approximately 110 mm Hg. If the sensor signal is indicative of flow rate, the lower threshold value may be approximately 500 ml/min and the upper threshold value may be approximately 700 ml/min for each kidney. In essence, the algorithm dictates activation or deactivation of the blood
perfusion modification device - The
control system 40 may operate as a closed loop utilizing feedback from thesensor 30, or as an open loop utilizing commands received byinput device 44. The open loop operation of thecontrol system 40 preferably utilizes some feedback from thesensor 30, but may also operate without feedback. Commands received by theinput device 44 may directly influence the control signal or may alter the software and related algorithms contained inmemory 42. The patient and/or treating physician may provide commands to inputdevice 44.Display 45 may be used to view the sensor signal and/or the software contained inmemory 42. - The control signal generated by the
control system 40 may be continuous, periodic, episodic or a combination thereof, as dictated by a preset or programmable algorithm contained inmemory 42. Continuous control signals include a constant pulse, a constant sequence of pulses, a triggered pulse and a triggered sequence of pulses. Examples of periodic control signals include each of the continuous control signals described above which have a designated start time (e.g., beginning of each minute, hour or day) and a designated duration (e.g., 1 second, 1 minute, 1 hour). Examples of episodic control signals include each of the continuous control signals described above which are triggered by an episode (e.g., activation by the patient/physician, an increase in blood pressure above a certain threshold, ECG, etc). - The
control system 40 may be implanted in whole or in part. For example, theentire control system 40 may be carried externally by the patient utilizing transdermal connections to thesensor lead 32 and thecontrol lead 38. Alternatively, thecontrol block 41 may be implanted with theinput device 44 anddisplay 45 carried externally by the patient utilizing transdermal connections therebetween. As a further alternative, the transdermal connections may be replaced by cooperating transmitters/receivers to remotely communicate between components of thecontrol system 40 and/or thesensor 30 and bloodperfusion modification device - Refer now to
FIG. 2 which schematically illustrates a renalvein flow regulator 50 in accordance with an embodiment of the present invention. Theflow regulator 50 may be intravascularly or extravascularly positioned in or on one or both renal veins 22 or downstream thereof on theinferior vena cava 16.Flow regulator 50 may be activated or deactivated by a control signal received fromcontrol cable 38. When activated, theflow regulator 50 constricts the renal vein 22 or otherwise reduces the cross sectional area of the lumen therein to create back pressure in the renovasculature, thereby increasing blood and interstitial pressure in the renal tissues. By creating back pressure in the renal tissues during episodes of reduced renal perfusion, therenal system 10 does not perceive the reduction in perfusion. - Refer now to
FIG. 3 which schematically illustrates aflow redirector 60 in accordance with another embodiment of the present invention. Theflow redirector 60 may be intravascularly or extravasculary positioned in or on the descendingaorta 14 downstream of the renal arteries 20, or in or on one or both of the common iliac arteries 28. Theflow redirector 60 may be activated or deactivated by a control signal received fromcontrol cable 38. When activated, theflow redirector 60 constricts the descending aorta or otherwise reduces the size of the lumen therein to redirect flow to the renal arteries 20 thereby increasing renovascular perfusion. By artificially increasing renovascular perfusion during a state of reduced cardiac output, renal artery constriction or renal artery stenosis, renal perfusion is preserved or enhanced. Preferably, theflow redirector 60 would be activated in such a manner as to minimize the effects on downstream perfusion into the lower extremities. - Refer now to
FIG. 4 which schematically illustrates an arterial blood flow pump 70 in accordance with another embodiment of the present invention. Thearterial flow pump 70 may be positioned intravascularly or extravascularly in or on the descendingaorta 14 upstream of the renal arteries 20 or in the renal arteries 20. Thearterial flow pump 70 may be activated and deactivated by a control signal received fromcontrol cable 38. When activated, thearterial flow pump 70 supplements arterial blood flow to the renal arteries 20 thereby increasing renal perfusion. - Refer now to
FIG. 5 which schematically illustrates a venous blood flow pump 80 in accordance with another embodiment of the present invention. Venous flow pump 80 may be intravascularly or extravascularly may be positioned in or on the renal veins 22, or in or on theinferior vena cava 16 downstream of the renal veins 22. Thevenous flow pump 80 may be activated and deactivated by a control signal received fromcontrol cable 38. When activated, thevenous flow pump 80 reduces blood flow or causes back flow in the renal veins 22 thereby increasing renal back pressure. - Refer now to
FIGS. 6 12 which illustrate various embodiments of flow regulators, flow redirectors and pumps that may be utilized for the blood perfusion tomodification devices FIGS. 2 5. Each ofFIGS. 6 12 schematically illustrate intravascular or extravascular devices disposed in or on ageneric vessel 90 having avascular wall 92 and avascular lumen 94. Thevessel 90 generically refers to the portion of the vasculature in or on which the bloodperfusion modification device FIGS. 6 12 are longitudinal cross sectional views unless otherwise specified and are generally circular in lateral cross section unless otherwise specified. - Refer now specifically to
FIGS. 6A and 6B which show side cross sectional schematic illustrations of an externalinflatable cuff 100 in accordance with an embodiment of the present invention.FIG. 6A illustrates theinflatable cuff 100 in the deactivated (unconstricted) state, andFIG. 6B illustrates theinflatable cuff 100 in the activated (constricted) state. Theinflatable cuff 100 may be used for the renalvein flow regulator 50 illustrated inFIG. 2 or theflow redirector 60 illustrated inFIG. 3 . Those skilled in the art will recognize theinflatable cuff 100 illustrated is merely schematic and is intended to generically refer to a wide variety of inflatable cuffs. Examples of inflatable cuffs that may be adapted for use in the present invention are disclosed in U.S. Pat. No. 4,256,094 to Kapp et al. and U.S. Pat. No. 4,881,939 to Newman, the entire disclosures of which are hereby incorporated by reference. -
Inflatable cuff 100 includes ahousing 102 which may be connected to thevessel wall 92 utilizing conventional techniques such assutures 104.Housing 102 contains an inflatableannular balloon 106 having an interior 107 which is in fluid communication with afluid line 108. Theballoon 106 may be an annular geometry with a central passageway to accommodate thevessel 90 therein as illustrated, or may be a geometry without a passageway and reside on one side of thevessel 90. In addition, oneballoon 106 may be utilized as shown, or a plurality ofballoons 106 may be utilized. - A pressure/vacuum source 110 (e.g., a closed volume piston pump) selectively inflates and deflates the
balloon 106 by way ofpressure line 108. The pressure/vacuum source 110 is preferably implanted, but may be carried externally by the patient with a transdermal connection to thepressure line 108. A saline liquid inflation fluid is preferred, but other fluids (i.e. liquids and gases) may be used. - The pressure/
vacuum source 110 is connected to thecontrol cable 38, which provides a control signal fromcontrol system 40 to activate or deactivate the pressure/vacuum source 110 and thereby inflate or deflate theballoon 106. When activated, the pressure/vacuum source 110 applies pressure and causes theballoon 106 to inflate thereby constricting thevascular wall 92 and obstructing or reducing the size of theinternal lumen 94. Theinternal lumen 94 may be partially or totally occluded by controlling the degree ofballoon 106 inflation. When deactivated, the pressure/vacuum source 110 applies vacuum and causes theballoon 106 to deflate thereby permitting thevascular wall 92 to return to its unconstricted state and restoring the nominal size of theinternal lumen 94. - The pressure/
vacuum source 110 may be automatically actuated by thecontrol system 40 as discussed above, or may be manually actuated. An example of an externally manually actuated pressure/vacuum source is disclosed in U.S. Pat. No. 4,709,690 to Haber, the entire disclosure of which is hereby incorporated by reference. Examples of transdermally manually actuated pressure/vacuum sources are disclosed in U.S. Pat. No. 4,586,501 to Claracq, U.S. Pat. No. 4,828,544 to Lane et al., and U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosures of which are hereby incorporated by reference. - In use, the
sensor 30 detects a reduction in renal perfusion or other change indicative of the need to activate the system as indicated by a sensor signal transmitted by way ofsensor cable 32 to thecontrol system 40. In response, thecontrol system 40 transmits a control signal as a function the sensor signal as dictated by the algorithm contained inmemory 42. The control signal is transmitted by way ofcontrol cable 38 to the pressure/vacuum source 110. Depending on the control signal, the pressurizedfluid source 110 is activated (pressure) or deactivated (vacuum) to inflate or deflate theballoon 106. - If the
inflatable cuff 100 is utilized as a renalvein flow regulator 50 as illustrated inFIG. 2 , the reduced size of thevascular lumen 94 causes back pressure in the renal veins 22 and ultimately the renal parenchyma and arterial circulation thereby causing an apparent increase in renovascular perfusion and pressure. If theinflatable cuff 100 is utilized as aflow redirector 60 as illustrated inFIG. 3 , the reduced size of thevascular lumen 94 causes blood to be redirected into the renal arteries 20 thereby causing an increase in renovascular perfusion. In either instance, renovascular perfusion and/or intrarenal pressure are maintained or augmented. -
Inflatable cuff 100 is one example of many different mechanisms for applying external compression to thevascular wall 92 to reduce the size of theinternal lumen 94. Other mechanisms for applying for external compression to thevascular wall 92 are described in greater detail with reference toFIGS. 8A , 8B, 9A and 9B. In addition to the specific mechanisms mentioned herein, those skilled in the art will recognize that to many other mechanisms may be adapted for this application. For example, external compression may be applied utilizing an electromagnetically actuated ferro fluid device as disclosed in the U.S. Pat. No. 5,509,888 to Miller, the entire disclosure of which is hereby incorporated by reference. Another example of an electromagnetically actuated ferro fluid type external compression device is disclosed in U.S. Pat. No. 4,053,952 to Goldstein, the entire disclosure of which is incorporated by reference. - Refer now to
FIGS. 7A and 7B which show cross sectional schematic illustrations of an internalinflatable balloon device 200 in accordance with another embodiment of the present invention.FIG. 7A illustrates theinflatable balloon device 200 in the deactivated (unconstricted) state, andFIG. 7B illustrates theinflatable balloon device 200 in the activated (constricted) state. Theinflatable balloon device 200 may be used for the renalvein flow regulator 50 illustrated inFIG. 2 or theflow redirector 60 illustrated inFIG. 3 . - Those skilled in the art will recognize that the internal
inflatable balloon device 200 is merely schematic and is intended to generically refer to a wide variety of internal occlusion devices. An example of an internal inflatable balloon device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 4,682,583 to Burton et al., the entire disclosure of which is hereby incorporated by reference. Another example of an internal inflatable balloon device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosure of which is hereby incorporated by reference. -
Inflatable balloon device 200 includes ahousing 202 which may be connected to the inside surface of thevessel wall 92 utilizing conventional techniques such as those used for implanting vascular stents, grafts and filters.Housing 202 includes an inflatableannular balloon 206 having an interior 207 which is in fluid communication with afluid line 208. Theballoon 206 may be an annular geometry with a central perfusion passageway as illustrated, or may be a geometry without a passageway and reside on one side of thevessel 90. In addition, oneballoon 206 may be utilized as shown, or a plurality ofballoons 206 may be used. - A pressure/
vacuum source 110 selectively inflates and deflates theballoon 206 by way ofpressure line 208. The pressure/vacuum source 110 is connected to thecontrol cable 38, which provides a control signal fromcontrol system 40 to activate or deactivate the pressure/vacuum source 110 and thereby inflate or deflate theballoon 206. When activated, the pressure/vacuum source 110 applies pressure and causes theballoon 206 to inflate thereby obstructing or reducing the size of theinternal lumen 94. Theinternal lumen 94 may be partially or totally occluded by adjusting the degree ofballoon 206 inflation. When deactivated, the pressure/vacuum source 110 applies vacuum and causes theballoon 206 to deflate thereby restoring the nominal size of theinternal lumen 94. The internalinflatable balloon device 200 basically operates on the same principles as theexternal compression device 100 described previously, except thatinflatable balloon device 200 does not utilize external compression, but rather totally or partially occludes thevascular lumen 94 without affecting thevascular wall 92. - Refer now to
FIGS. 8A and 8B which show side cross sectional schematic illustrations of apiston device 300 in accordance with another embodiment of the present invention.FIG. 8A illustrates thepiston device 300 in the deactivated (unconstricted) state, andFIG. 8B illustrates thepiston device 300 in the activated (constricted) state. Thepiston device 300 may be used for the renalvein flow regulator 50 illustrated inFIG. 2 or theflow redirector 60 illustrated inFIG. 3 . Those skilled in the art will recognize that thepiston device 300 illustrated is merely schematic and is intended to generically refer to a wide variety of piston type devices. An example of a piston type device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 4,014,318 to Dockum et al., the entire disclosure of which is hereby incorporated by reference. -
Piston device 300 includes ahousing 302 which may be connected to thevessel wall 92 utilizing conventional techniques such assutures 304.Housing 302 includes aninternal chamber 307 in whichpiston 306 is slidably disposed. Theinternal chamber 307 is in fluid communication with afluid line 308. A pressure/vacuum source 110 selectively fills an empties thechamber 307 by way ofpressure line 308. The pressure/vacuum source 110 is connected to thecontrol cable 38, which provides a control signal fromcontrol system 40 to activate or deactivate the pressure/vacuum source 110. - When activated, the pressure/
vacuum source 110 fills theinternal chamber 307 with fluid thereby displacing thepiston 306 to constrict thevascular wall 92 and reduce the size of theinternal lumen 94. Theinternal lumen 94 may be partially or totally occluded by adjusting the displacement distance of thepiston 306. When deactivated, the pressure/vacuum source 110 empties theinternal chamber 307 causing thepiston 306 to be displaced back into thechamber 307 thereby permitting thevascular wall 92 to return to its unconstricted state and restoring the nominal size of theinternal lumen 94. The function and use of thepiston device 300 is otherwise essentially the same as the otherexternal compression device 100 discussed previously. - As illustrated and described, the
piston device 300 operates by hydraulic actuation. Alternatively, thepiston device 300 may operate by electromagnetic actuation such as provided by a solenoid device. An example of an electromagnetic solenoid device is disclosed in Dockum et al. '318 mentioned previously. If electromagnetic actuation is utilized, the pressure/vacuum source 110 may be replaced by a suitable amplifier to power the electromagnets in the solenoid. The function and use of the solenoid alternative is otherwise essentially the same as the hydraulic embodiment discussed above. - Refer now to
FIGS. 9A and 9B which show side cross sectional schematic illustrations of arotatable ring device 400 in accordance with another embodiment of the present invention.FIG. 9A illustrates therotatable ring device 400 in the deactivated (unconstricted) state andFIG. 9B illustrates therotatable ring device 400 in the activated (constricted) state. Therotatable ring device 400 may be used for the renalvein flow regulator 50 illustrated inFIG. 2 or theflow redirector 60 illustrated inFIG. 3 . Those skilled in the art will recognize that therotatable ring device 400 is merely schematic and is intended to generically refer to a wide variety of rotatable ring devices. An example of a rotatable ring device that may be adapted for use in the present invention is disclosed in U.S. Pat. No. 4,551,862 to Haber, the entire disclosure of which is hereby incorporated by reference. -
Rotatable ring device 400 includes ahousing 402 which may be connected to thevessel wall 92 utilizing conventional techniques such assutures 404.Housing 402 includes one ormore rings 406 which are operably connected to alinear actuation cable 408 to cause rotation of the ring or rings 406 substantially as described in Haber '862. Thelinear actuation cable 408 is connected to asolenoid device 410 which selectively pushes or pulls thelinear actuation cable 408 to cause clockwise or counter clockwise rotation of the rotatable rings 406. - The
solenoid device 410 is connected to thecontrol cable 38 which provides a control signal from thecontrol system 40 to activate or deactivate thesolenoid device 410 and thereby rotate therings 406. When activated, thesolenoid 410 causes the rotatable rings 406 to constrict thevascular wall 92 and reduce the size of thelumen 94. Theinternal lumen 94 may be partially or totally occluded by adjusting the degree of rotation of therings 406. When deactivated, thesolenoid device 410 causes the rotatable rings to unconstrict thereby permitting thevascular wall 92 to return to its unconstricted state and restoring the nominal size of theinternal lumen 94. The function and use of therotatable ring device 400 is otherwise substantially the same as the otherexternal compression devices - Refer now to
FIG. 10 which shows a side cross sectional schematic illustration of anexternal pump 500 in accordance with an embodiment of the present invention.FIG. 10 illustrates thepump 500 in the deactivated state. Theexternal pump 500 may be used for thearterial flow pump 70 illustrated inFIG. 4 or thevenous flow pump 80 inFIG. 5 . Those skilled in the art will recognize that theexternal pump 500 is merely schematic and is intended to generically refer to a wide variety of extraluminal vascular pumps. An example of an extraluminal vascular pump that may be adapted for use in the present invention is disclosed in Dockum et al. '318 mentioned previously. -
Extraluminal pump 500 includes ahousing 502 which may be connected to thevessel wall 92 utilizing conventional techniques such assutures 504.Housing 502 includes a plurality ofinflatable balloons 506 each having an interior 507 which is in fluid communication with a plurality offluid lines 508. Fluid communication to each of theballoons 506 is maintained by separate lumens within thefluid line 508 such that theballoons 506 may be inflated independently. - A pressure/
vacuum source 110 is fluidly connected to a manifold 510 which sequentially inflates and deflates each of theballoons 506 to cause a sequence of constrictions about thevessel wall 92, thereby creating a pumping action within thevascular lumen 94. The direction and speed of the inflation sequence may be modified to change the pumping direction and flow rate. The pressure/vacuum source 110 is connected to thecontrol cable 38 which provides a control signal from thecontrol system 40 to activate and deactivate the pressure/vacuum source 110 andmanifold 510. When activated, the pressure/vacuum source 110 and manifold 510 cause theballoons 506 to sequentially inflate thereby producing the pumping action. After theballoons 506 have been sequentially inflated, the pressure/vacuum source 110 applies a vacuum to deflate theballoons 506. The pressure/vacuum source 110 andmanifold 510 may be reactivated to initiate another pumping cycle. If no further pumping action is desired, the pressure/vacuum source 110 maintains a vacuum such that theballoons 506 remain deflated. - If the
external pump 500 is used for thearterial flow pump 70 illustrated inFIG. 4 , theexternal pump 500 selectively supplements arterial blood flow and/or perfusion pressure to therenal arteries 200 thereby increasing renal perfusion. If theexternal pump 500 is utilized for thevenous flow pump 80 illustrated inFIG. 5 , theexternal pump 500 reduces blood flow or causes back flow in the renal veins 22 thereby increasing renal back pressure. In either instance, the renovascular perfusion and/or intrarenal pressure are maintained or augmented. - The
external pump 500 may utilize hydraulically actuatedballoons 506 as illustrated and described, or may utilize hydraulically actuated pistons similar to the embodiment described with reference toFIGS. 8A and 8B . Alternatively, the pistons may be electromagnetically actuated as with a solenoid type device as described in Dockum et al. '318 and as described with reference to the alternative embodiment ofFIGS. 8A and 8B . Thus, theexternal pump 500 may be hydraulically actuated by utilizingballoons 506, or may be hydraulically or electromagnetically actuated by replacing theballoons 506 with pistons slidably disposed in chambers. - Refer now to
FIG. 11 which shows a side cross sectional schematic illustration of aninternal pump 600 in accordance with an embodiment of the present invention.FIG. 11 illustrates theintraluminal pump 600 in the static or deactivated state. Theintraluminal pump 600 may be utilized for thearterial flow pump 70 illustrated inFIG. 4 or thevenous flow pump 80 illustrated inFIG. 5 . Those skilled in the art will recognize that theintraluminal pump 600 is merely schematic and is intended to generically wide variety of intraluminal vascular pumps. An example of an intraluminal vascular pump suitable for use in the present invention is disclosed in U.S. Pat. No. 5,692,882 to Bozeman, Jr. et al., the entire disclosure of which is hereby incorporated by reference. - The
intraluminal pump 600 includes ahousing 602 which may be connected to thevessel wall 92 utilizing the same anchoring techniques used by intravascular stents, to grafts and filters.Housing 602 includes proximal anddistal struts 603 which supportrotatable axle 604. One ormore impeller blades 605 are rigidly connected to theaxle 604 and rotate relative to thehousing 602 and struts 603. When theimpeller blades 605 are rotated, blood in thevascular lumen 94 is biased in the proximal or distal direction.Impeller blades 605 may be formed of a ferrous material suitable for forming into permanent magnets. Alternatively, theimpeller blades 605 may be formed of a nonferrous material but include a ferrous material disposed thereon for forming into permanent magnets. - The
housing 602 includes a plurality ofelectrical windings 606 which may be selectively activated byelectrical cable 608.Electrical cable 608 is connected topower amplifier 610 which may be selectively activated or deactivated by thecontrol system 40 by way ofcontrol cable 38. By activating thepower amplifier 610, electrical power is supplied to thecoil windings 606 in thehousing 602. Thecoil windings 606 generate a magnetic field causing the permanent magnets disposed on theimpeller blade 605 to be displaced.Multiple coil windings 606 may be utilized about the periphery of thehousing 602 to sequentially activate and deactivate magnetic fields causing rotation of theimpeller blades 605. The direction and frequency of the sequential activation may be modified to change the direction and speed of rotation, and thus the direction and degree of pumping action. As an alternative, supplemental fluid may be supplied to thepump 600 by connection to a source of blood within the body or by connection to a fluid reservoir containing a suitable fluid such as saline. The function and use ofinternal pump 600 is otherwise essentially the same asexternal pump 500. - Refer now to
FIG. 12 which shows a side cross sectional schematic illustration of adrug delivery device 700 in accordance with an embodiment of the present invention. Those skilled in the art will recognize that other site specific drug delivery devices may be utilized in place of thedelivery device 700 illustrated.Delivery device 700 includes ahousing 702 which may be connected thevessel wall 92 utilizing conventional techniques such assutures 705.Housing 702 includes anannular recess 705 which is in fluid communication with afluid delivery line 708.Annular recess 705 is open to the exterior of thevascular wall 92.Housing 702 includesannular seals 706 disposed proximally and distally of theannular recess 705 to create a fluid tight seal between thehousing 702 and thevascular wall 92. By creating a fluid tight seal, theannular seals 706 maintain fluid in theannular recess 705. With this arrangement, fluid delivered to theannular recess 705 viafluid delivery lines 708 remains in intimate contact with the exterior of thevascular wall 92 at the desired location. -
Fluid line 708 is connected to a fluid delivery pump/reservoir 710 which is connected to thecontrol cable 38. Thecontrol cable 38 provides a control signal from thecontrol system 40 to activate or deactivate the pump/reservoir 710. By selectively activating the pump/reservoir 710, fluid contained in thereservoir 710 is delivered to theannular recess 705 by way offluid line 708. The fluid contained in thereservoir 710 is preferably a vasoconstrictor such as phenylephrine. Alternatively or in addition, the reservoir may contain a vasodilator such as hydralazine or nitroprusside. - Accordingly, when the pump/
reservoir 710 is activated, the vasoconstrictor is delivered to theannular recess 705 thereby constricting thevascular wall 92 and obstructing or reducing the size of theinternal lumen 94.Internal lumen 94 may be partially or totally closed by varying the amount and strength of the vasoconstrictor. When deactivated, the pump/reservoir 710 may deliver a dilution fluid or a vasodilator to reduce or reverse the effects of the vasoconstrictor, thereby permitting or causing thevascular wall 92 to return to its unconstricted state and restoring the nominal size of theinternal lumen 94. The function and use of thevasoconstrictor delivery device 700 is otherwise substantially the same as theexternal compression devices - From the foregoing, it should be apparent to those skilled in the art that the present invention provides a number of
devices systems - Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departures in form and detail may be made without departing from the scope and spirit of the present invention as described in the appended claims.
Claims (38)
1. A method of treating a patient comprising the steps of:
providing a blood perfusion modification device, wherein the modification device comprises a flow redirector, and wherein the flow redirector is positioned downstream of a renal artery to redirect blood flow to the renal artery;
positioning the blood perfusion modification device in the patient's renovascular circulation or immediately adjacent thereto; and
activating, deactivating or otherwise modifying the blood perfusion modification device to cause an increase in renal perfusion.
2. A method as in claim 1 , wherein the flow redirector is positioned in a descending aorta downstream of the renal artery to redirect blood flow to the renal artery.
3. A method as in claim 1 , wherein the flow redirector is positioned in a common iliac artery downstream of the renal artery to redirect blood flow to the renal artery.
4. A method as in claim 1 , wherein the modification device comprises a pump, and wherein the pump is positioned upstream of a renal artery to supplement blood flow therein.
5. A method as in claim 1 , wherein the modification device comprises a pump, and wherein the pump is positioned downstream of a renal vein to reduce blood flow or causes back flow therein.
6. A method as in claim 1 , wherein the modification device comprises a drug delivery device, and wherein the drug delivery device is positioned patient's renovascular circulation or immediately adjacent thereto.
7. A method as in claim 1 , wherein the modification device is positioned intravascularly.
8. A method as in claim 1 , wherein the modification device is positioned extravascularly.
9. A system for treating a patient, the system comprising:
a blood perfusion modification device positioned in the patient's renovascular circulation or immediately adjacent thereto;
a sensor dimensioned and configured to be positioned upstream of the blood perfusion modification device and upstream of the kidney of the patient to generate a signal indicative of a need to modify renal perfusion; and
a control system operably connected to the sensor and blood perfusion modification device, wherein the control system generates a control signal to activate, deactivate or otherwise modify the blood perfusion modification device as a function of the sensor signal to cause an increase in renal perfusion.
10-16. (canceled)
17. A system as in claim 9 , wherein the modification device comprises a flow redirector dimensioned and configured to be positioned downstream of a renal artery to redirect blood flow to the renal artery.
18. A system as in claim 17 , wherein the flow redirector is dimensioned and configured to be positioned extravascularly.
19. A system as in claim 18 , wherein the flow redirector comprises an inflatable cuff.
20. A system as in claim 18 , wherein the flow redirector comprises a rotatable ring.
21. A system as in claim 18 , wherein the flow redirector comprises a piston.
22. A system as in claim 17 , wherein the flow redirector is dimensioned and configured to be positioned intravascularly.
23. A system as in claim 22 , wherein the flow redirector comprises an inflatable balloon.
24. A system as in claim 9 , wherein the modification device comprises a pump positioned upstream of a renal artery to supplement blood flow therein.
25. A system as in claim 9 , wherein the modification device comprises a pump positioned downstream of a renal vein to reduce blood flow or causes back flow therein.
26. A system as in claim 9 , wherein the modification device comprises a drug delivery device dimensioned and configured to be positioned in or on the patient's renovascular circulation.
27. A system as in claim 9 , wherein the control system includes a processor and a memory.
28. A system as in claim 27 , wherein the memory includes software containing an algorithm defining a relationship between the control signal and the sensor signal.
29. A system as in claim 28 , wherein the algorithm dictates an activation, deactivation or modification control signal when the sensor signal falls below or rises above a predetermined threshold value.
30. A method for treating a patient comprising:
implanting a blood perfusion modification device in the renovascular circulation of a patient or immediately adjacent thereto;
activating, deactivating or otherwise modifying the blood perfusion modification device to cause an increase in renal perfusion; and
wherein the modification device comprises a flow redirector, and wherein the flow redirector is positioned downstream of a renal artery to redirect blood flow to the renal artery.
31. A method as in claim 30 , wherein the flow redirector is positioned in a descending aorta downstream of the renal artery to redirect blood flow to the renal artery.
32. A method as in claim 30 , wherein the flow redirector is positioned in a common iliac artery downstream of the renal artery to redirect blood flow to the renal artery.
33. A method as in claim 30 , wherein the modification device comprises a pump, and wherein the pump is positioned upstream of a renal artery to supplement blood flow therein.
34. A method as in claim 30 , wherein the modification device comprises a pump, and wherein the pump is positioned downstream of a renal vein to reduce blood flow or causes back flow therein.
35. A method as in claim 30 , wherein the modification device comprises a drug delivery device, and wherein the drug delivery device is positioned in patient's renovascular circulation or immediately adjacent thereto.
36. A method as in claim 30 , wherein the modification device is positioned intravascularly.
37. A method as in claim 30 , wherein the modification device is positioned extravascularly.
38. A method of treating renal disorders or hypertension, comprising:
implanting a first renal modulation device that contributes to renal function of a first kidney of a patient;
implanting a second renal modulation device that contributes to renal function of a second kidney of the patient; and
activating and/or deactivating the first renal modulation device and/or the second renal modulation device so to achieve bilateral renal neurohormonal modulation.
39. A method for selectively and controllably increasing renal perfusion, comprising:
positioning a renal modulation device proximate the renal vasculature;
providing a means for sensing cardiac output and/or renal perfusion; and
activating and/or deactivating the renal modulation device during periods of decreased cardiac output or suboptimal renal perfusion, so as to reduce or reverse neurohormonal activation and/or fluid retention.
40. A method, comprising:
implanting a renal modulation device adjacent to an elongated biological structure associated with renal function proximate a kidney of the patient, wherein the renal modulation device includes a cuff placed around a renal blood vessel of the kidney; and
causing the renal modulation device to be activated so as to at least partially block the renal vessel.
41. A method of treating renal disorders or hypertension, comprising:
providing a first renal modulation device that contributes to renal function of a first kidney of a patient;
providing a second renal modulation device that contributes to renal function of a second kidney of the patient; and
providing instructions, including:
implanting the first renal modulation device proximate a biological structure associated with renal function;
implanting the second renal modulation device proximate a biological structure associated with renal function;
activating and/or deactivating the first renal modulation device and/or the second renal modulation device so to achieve bilateral renal neurohormonal modulation.
42. A method for selectively and controllably increasing renal perfusion, comprising:
providing a renal modulation device;
providing a means for sensing cardiac output and/or renal perfusion;
providing instructions, including:
positioning a renal modulation device proximate the renal vasculature;
activating and/or deactivating the renal modulation device during periods of decreased cardiac output or suboptimal renal perfusion, so as to reduce or reverse neurohormonal activation and/or fluid retention.
43. A method, comprising:
providing a renal modulation device, including a cuff;
providing instructions, including:
implanting the renal modulation device adjacent to an elongated biological structure associated with renal function proximate a kidney of the patient, such that the cuff placed around a renal blood vessel of the kidney; and
activating the renal modulation device so as to at least partially block the renal vessel.
44. An apparatus, comprising:
a renal modulation device configured for placement proximate the renal vasculature; and
a controller configured to operate based on instructions to control activation of renal baroreceptors with the renal modulation device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/345,095 US20090105631A1 (en) | 2000-10-30 | 2008-12-29 | Systems and methods for controlling renovascular perfusion |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/702,089 US6616624B1 (en) | 2000-10-30 | 2000-10-30 | Systems and method for controlling renovascular perfusion |
US10/453,678 US7485104B2 (en) | 2000-10-30 | 2003-06-02 | Systems and methods for controlling renovascular perfusion |
US12/345,095 US20090105631A1 (en) | 2000-10-30 | 2008-12-29 | Systems and methods for controlling renovascular perfusion |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/453,678 Continuation US7485104B2 (en) | 2000-10-30 | 2003-06-02 | Systems and methods for controlling renovascular perfusion |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090105631A1 true US20090105631A1 (en) | 2009-04-23 |
Family
ID=27789378
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/702,089 Expired - Lifetime US6616624B1 (en) | 2000-10-30 | 2000-10-30 | Systems and method for controlling renovascular perfusion |
US10/453,678 Expired - Lifetime US7485104B2 (en) | 2000-10-30 | 2003-06-02 | Systems and methods for controlling renovascular perfusion |
US12/345,095 Abandoned US20090105631A1 (en) | 2000-10-30 | 2008-12-29 | Systems and methods for controlling renovascular perfusion |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/702,089 Expired - Lifetime US6616624B1 (en) | 2000-10-30 | 2000-10-30 | Systems and method for controlling renovascular perfusion |
US10/453,678 Expired - Lifetime US7485104B2 (en) | 2000-10-30 | 2003-06-02 | Systems and methods for controlling renovascular perfusion |
Country Status (1)
Country | Link |
---|---|
US (3) | US6616624B1 (en) |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262389A1 (en) * | 2005-12-22 | 2008-10-23 | P. Square Medical Ltd. | Monitoring conditions of a patient's urinary system |
US20110125061A1 (en) * | 2006-12-20 | 2011-05-26 | P Square Medical Ltd. | Monitoring Conditions Of A Patient's Urinary System |
US20110287398A1 (en) * | 2010-05-19 | 2011-11-24 | C. R. Bard, Inc. | Demonstration mannequin for simulating catheter malposition |
WO2013070186A1 (en) * | 2011-11-07 | 2013-05-16 | California Institute Of Technology | Correction and optimization of wave reflection in blood vessels |
US8880185B2 (en) | 2010-06-11 | 2014-11-04 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US8939970B2 (en) | 2004-09-10 | 2015-01-27 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US8951251B2 (en) | 2011-11-08 | 2015-02-10 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9028472B2 (en) | 2011-12-23 | 2015-05-12 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9079000B2 (en) | 2011-10-18 | 2015-07-14 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
US9125667B2 (en) | 2004-09-10 | 2015-09-08 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
US9125666B2 (en) | 2003-09-12 | 2015-09-08 | Vessix Vascular, Inc. | Selectable eccentric remodeling and/or ablation of atherosclerotic material |
US9125655B2 (en) | 2010-07-16 | 2015-09-08 | California Institute Of Technology | Correction and optimization of wave reflection in blood vessels |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US9173696B2 (en) | 2012-09-17 | 2015-11-03 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
US9186209B2 (en) | 2011-07-22 | 2015-11-17 | Boston Scientific Scimed, Inc. | Nerve modulation system having helical guide |
US9186210B2 (en) | 2011-10-10 | 2015-11-17 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
US9220561B2 (en) | 2011-01-19 | 2015-12-29 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
US9277955B2 (en) | 2010-04-09 | 2016-03-08 | Vessix Vascular, Inc. | Power generating and control apparatus for the treatment of tissue |
US9297845B2 (en) | 2013-03-15 | 2016-03-29 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
US9327100B2 (en) | 2008-11-14 | 2016-05-03 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US9433760B2 (en) | 2011-12-28 | 2016-09-06 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
US9463066B2 (en) | 2002-04-08 | 2016-10-11 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9486355B2 (en) | 2005-05-03 | 2016-11-08 | Vessix Vascular, Inc. | Selective accumulation of energy with or without knowledge of tissue topography |
US9579030B2 (en) | 2011-07-20 | 2017-02-28 | Boston Scientific Scimed, Inc. | Percutaneous devices and methods to visualize, target and ablate nerves |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9649156B2 (en) | 2010-12-15 | 2017-05-16 | Boston Scientific Scimed, Inc. | Bipolar off-wall electrode device for renal nerve ablation |
US9656009B2 (en) | 2007-07-11 | 2017-05-23 | California Institute Of Technology | Cardiac assist system using helical arrangement of contractile bands and helically-twisting cardiac assist device |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9687166B2 (en) | 2013-10-14 | 2017-06-27 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
US9693821B2 (en) | 2013-03-11 | 2017-07-04 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US9713483B2 (en) | 1995-10-13 | 2017-07-25 | Medtronic Vascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US9808300B2 (en) | 2006-05-02 | 2017-11-07 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
US9814873B2 (en) | 2002-04-08 | 2017-11-14 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US9827039B2 (en) | 2013-03-15 | 2017-11-28 | Boston Scientific Scimed, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9833283B2 (en) | 2013-07-01 | 2017-12-05 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US9895194B2 (en) | 2013-09-04 | 2018-02-20 | Boston Scientific Scimed, Inc. | Radio frequency (RF) balloon catheter having flushing and cooling capability |
US9907609B2 (en) | 2014-02-04 | 2018-03-06 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
US9919144B2 (en) | 2011-04-08 | 2018-03-20 | Medtronic Adrian Luxembourg S.a.r.l. | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
US9925001B2 (en) | 2013-07-19 | 2018-03-27 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
US9943365B2 (en) | 2013-06-21 | 2018-04-17 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9962223B2 (en) | 2013-10-15 | 2018-05-08 | Boston Scientific Scimed, Inc. | Medical device balloon |
US9968611B2 (en) | 2002-04-08 | 2018-05-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US9974607B2 (en) | 2006-10-18 | 2018-05-22 | Vessix Vascular, Inc. | Inducing desirable temperature effects on body tissue |
US10022182B2 (en) | 2013-06-21 | 2018-07-17 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation having rotatable shafts |
US20180206974A1 (en) * | 2017-01-25 | 2018-07-26 | W. L. Gore & Associates, Inc. | Method and device for treatment and prevention of fluid overload in patients with heart failure |
US10034708B2 (en) | 2002-04-08 | 2018-07-31 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for thermally-induced renal neuromodulation |
US10085799B2 (en) | 2011-10-11 | 2018-10-02 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US10124195B2 (en) | 2002-04-08 | 2018-11-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermally-induced renal neuromodulation |
US10130792B2 (en) | 2002-04-08 | 2018-11-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
US10271898B2 (en) | 2013-10-25 | 2019-04-30 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
US10321946B2 (en) | 2012-08-24 | 2019-06-18 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices with weeping RF ablation balloons |
US10342609B2 (en) | 2013-07-22 | 2019-07-09 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US10350004B2 (en) | 2004-12-09 | 2019-07-16 | Twelve, Inc. | Intravascular treatment catheters |
US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
US10413357B2 (en) | 2013-07-11 | 2019-09-17 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
US10660698B2 (en) | 2013-07-11 | 2020-05-26 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
US10695124B2 (en) | 2013-07-22 | 2020-06-30 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
US10722300B2 (en) | 2013-08-22 | 2020-07-28 | Boston Scientific Scimed, Inc. | Flexible circuit having improved adhesion to a renal nerve modulation balloon |
US10835305B2 (en) | 2012-10-10 | 2020-11-17 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices and methods |
US10945786B2 (en) | 2013-10-18 | 2021-03-16 | Boston Scientific Scimed, Inc. | Balloon catheters with flexible conducting wires and related methods of use and manufacture |
US10952790B2 (en) | 2013-09-13 | 2021-03-23 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
US11166676B2 (en) * | 2017-12-11 | 2021-11-09 | Marina I. Adrianzen Fonseca | Real-time kidney monitoring medical device |
US11202671B2 (en) | 2014-01-06 | 2021-12-21 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
US11510679B2 (en) | 2017-09-21 | 2022-11-29 | W. L. Gore & Associates, Inc. | Multiple inflation endovascular medical device |
US11883030B2 (en) | 2022-04-29 | 2024-01-30 | inQB8 Medical Technologies, LLC | Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature |
US11974751B2 (en) | 2022-04-29 | 2024-05-07 | inQB8 Medical Technologies, LLC | Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature |
Families Citing this family (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097618B1 (en) * | 2003-03-12 | 2006-08-29 | Transoma Medical, Inc. | Devices and methods for detecting and treating inadequate tissue perfusion |
US20060064135A1 (en) * | 1997-10-14 | 2006-03-23 | Transoma Medical, Inc. | Implantable pressure sensor with pacing capability |
US6702811B2 (en) | 1999-04-05 | 2004-03-09 | Medtronic, Inc. | Ablation catheter assembly with radially decreasing helix and method of use |
EP1229839A4 (en) | 1999-10-25 | 2005-12-07 | Therus Corp | Use of focused ultrasound for vascular sealing |
US6626855B1 (en) | 1999-11-26 | 2003-09-30 | Therus Corpoation | Controlled high efficiency lesion formation using high intensity ultrasound |
US6616624B1 (en) * | 2000-10-30 | 2003-09-09 | Cvrx, Inc. | Systems and method for controlling renovascular perfusion |
US8974446B2 (en) | 2001-10-11 | 2015-03-10 | St. Jude Medical, Inc. | Ultrasound ablation apparatus with discrete staggered ablation zones |
US8150520B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods for catheter-based renal denervation |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US20110207758A1 (en) | 2003-04-08 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Therapeutic Renal Denervation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US7261733B1 (en) * | 2002-06-07 | 2007-08-28 | Endovascular Technologies, Inc. | Endovascular graft with sensors design and attachment methods |
US7801596B2 (en) * | 2002-09-20 | 2010-09-21 | Angel Medical Systems, Inc. | Physician's programmer for implantable devices having cardiac diagnostic and patient alerting capabilities |
TW200501913A (en) * | 2003-01-15 | 2005-01-16 | Univ Miami | Venous anti-reflux implant |
US20050165317A1 (en) * | 2003-11-04 | 2005-07-28 | Turner Nicholas M. | Medical devices |
US20050102835A1 (en) * | 2003-11-14 | 2005-05-19 | Trewiler Gary E. | Method for repairing gas turbine rotor blades |
US8938300B2 (en) * | 2004-05-04 | 2015-01-20 | University Of Rochester | Leadless implantable intravascular electrophysiologic device for neurologic/cardiovascular sensing and stimulation |
US8849416B2 (en) | 2004-05-04 | 2014-09-30 | University Of Rochester | Implantable bio-electro-physiologic interface matrix |
EP1753506A4 (en) * | 2004-05-04 | 2008-06-11 | Univ Rochester | Leadless implantable cardioverter defibrillator |
CA2567769A1 (en) * | 2004-05-10 | 2005-11-24 | Transoma Medical, Inc. | Portable device for monitoring electrocardiographic signals and indices of blood flow |
US7410465B2 (en) * | 2004-09-30 | 2008-08-12 | Laufer Michael D | Devices for counteracting hypotension |
US20060074453A1 (en) * | 2004-10-04 | 2006-04-06 | Cvrx, Inc. | Baroreflex activation and cardiac resychronization for heart failure treatment |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US8226592B2 (en) * | 2004-12-15 | 2012-07-24 | Rox Medical, Inc. | Method of treating COPD with artificial arterio-venous fistula and flow mediating systems |
US20070016089A1 (en) * | 2005-07-15 | 2007-01-18 | Fischell David R | Implantable device for vital signs monitoring |
US20070021803A1 (en) | 2005-07-22 | 2007-01-25 | The Foundry Inc. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US9642726B2 (en) | 2005-07-25 | 2017-05-09 | Vascular Dynamics, Inc. | Devices and methods for control of blood pressure |
US8862243B2 (en) | 2005-07-25 | 2014-10-14 | Rainbow Medical Ltd. | Electrical stimulation of blood vessels |
US8923972B2 (en) | 2005-07-25 | 2014-12-30 | Vascular Dynamics, Inc. | Elliptical element for blood pressure reduction |
US9125567B2 (en) | 2005-07-25 | 2015-09-08 | Vascular Dynamics, Inc. | Devices and methods for control of blood pressure |
US9592136B2 (en) | 2005-07-25 | 2017-03-14 | Vascular Dynamics, Inc. | Devices and methods for control of blood pressure |
US9125732B2 (en) | 2005-07-25 | 2015-09-08 | Vascular Dynamics, Inc. | Devices and methods for control of blood pressure |
US20070213616A1 (en) | 2005-10-20 | 2007-09-13 | Thomas Anderson | Systems and methods for arteriotomy localization |
WO2007075593A1 (en) * | 2005-12-20 | 2007-07-05 | The Cleveland Clinic Foundation | Apparatus and method for modulating the baroreflex system |
CA2637787A1 (en) | 2006-02-03 | 2007-08-16 | Synecor, Llc | Intravascular device for neuromodulation |
WO2007127477A2 (en) * | 2006-04-27 | 2007-11-08 | Synecor, Llc | Renal blood flow augmentation for congestive heart failure treatment |
ATE494040T1 (en) * | 2006-06-28 | 2011-01-15 | Ardian Inc | SYSTEMS FOR HEAT-INDUCED RENAL NEUROMODULATION |
US7744618B2 (en) * | 2006-12-07 | 2010-06-29 | Cardiac Pacemakers, Inc. | Device and method for modulating renal function |
US8150521B2 (en) * | 2007-03-15 | 2012-04-03 | Cvrx, Inc. | Methods and devices for controlling battery life in an implantable pulse generator |
US8594794B2 (en) | 2007-07-24 | 2013-11-26 | Cvrx, Inc. | Baroreflex activation therapy with incrementally changing intensity |
TWI377960B (en) * | 2007-08-07 | 2012-12-01 | Nat Health Research Institutes | Blood flow control system and tension adjustable instrument |
US8702640B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | System, devices, and methods including catheters configured to monitor and inhibit biofilm formation |
US8647292B2 (en) | 2007-08-17 | 2014-02-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states |
US8706211B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having self-cleaning surfaces |
US8753304B2 (en) | 2007-08-17 | 2014-06-17 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter |
US8366652B2 (en) | 2007-08-17 | 2013-02-05 | The Invention Science Fund I, Llc | Systems, devices, and methods including infection-fighting and monitoring shunts |
US8734718B2 (en) | 2007-08-17 | 2014-05-27 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component |
US8460229B2 (en) * | 2007-08-17 | 2013-06-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states |
US8961448B2 (en) * | 2008-01-28 | 2015-02-24 | Peter Forsell | Implantable drainage device |
US8626299B2 (en) | 2008-01-31 | 2014-01-07 | Enopace Biomedical Ltd. | Thoracic aorta and vagus nerve stimulation |
US8538535B2 (en) | 2010-08-05 | 2013-09-17 | Rainbow Medical Ltd. | Enhancing perfusion by contraction |
US8626290B2 (en) | 2008-01-31 | 2014-01-07 | Enopace Biomedical Ltd. | Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta |
US7925352B2 (en) | 2008-03-27 | 2011-04-12 | Synecor Llc | System and method for transvascularly stimulating contents of the carotid sheath |
US20100211131A1 (en) * | 2008-04-07 | 2010-08-19 | Williams Michael S | Intravascular system and method for blood pressure control |
US8329450B2 (en) * | 2008-08-01 | 2012-12-11 | Biomedinnovations, Llc | Methods and apparatus for organ support |
US20120041287A1 (en) | 2008-12-04 | 2012-02-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including implantable devices with anti-microbial properties |
US20110208021A1 (en) * | 2008-12-04 | 2011-08-25 | Goodall Eleanor V | Systems, devices, and methods including implantable devices with anti-microbial properties |
US8585627B2 (en) | 2008-12-04 | 2013-11-19 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure |
WO2010065135A1 (en) | 2008-12-04 | 2010-06-10 | Searete, Llc | System, devices, and methods including actively-controllable sterilizing excitation delivery implants |
US20110208023A1 (en) * | 2008-12-04 | 2011-08-25 | Goodall Eleanor V | Systems, devices, and methods including implantable devices with anti-microbial properties |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8808345B2 (en) | 2008-12-31 | 2014-08-19 | Medtronic Ardian Luxembourg S.A.R.L. | Handle assemblies for intravascular treatment devices and associated systems and methods |
US20110092880A1 (en) | 2009-10-12 | 2011-04-21 | Michael Gertner | Energetic modulation of nerves |
US20110118600A1 (en) | 2009-11-16 | 2011-05-19 | Michael Gertner | External Autonomic Modulation |
US9174065B2 (en) | 2009-10-12 | 2015-11-03 | Kona Medical, Inc. | Energetic modulation of nerves |
US8986231B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US8469904B2 (en) | 2009-10-12 | 2013-06-25 | Kona Medical, Inc. | Energetic modulation of nerves |
US8986211B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US20160059044A1 (en) | 2009-10-12 | 2016-03-03 | Kona Medical, Inc. | Energy delivery to intraparenchymal regions of the kidney to treat hypertension |
US8517962B2 (en) | 2009-10-12 | 2013-08-27 | Kona Medical, Inc. | Energetic modulation of nerves |
US9119951B2 (en) | 2009-10-12 | 2015-09-01 | Kona Medical, Inc. | Energetic modulation of nerves |
US11998266B2 (en) | 2009-10-12 | 2024-06-04 | Otsuka Medical Devices Co., Ltd | Intravascular energy delivery |
US8295912B2 (en) | 2009-10-12 | 2012-10-23 | Kona Medical, Inc. | Method and system to inhibit a function of a nerve traveling with an artery |
US20110112400A1 (en) * | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
EP2498706B1 (en) | 2009-11-13 | 2016-04-20 | St. Jude Medical, Inc. | Assembly of staggered ablation elements |
EP2525715A4 (en) * | 2010-01-19 | 2014-06-04 | Medtronic Ardian Luxembourg S R L | Methods and apparatus for renal neuromodulation via stereotactic radiotherapy |
CN102844074B (en) | 2010-02-17 | 2016-06-08 | 弗洛福沃德医药股份有限公司 | It is used for increasing the system and method for vein overall diameter |
US9555174B2 (en) | 2010-02-17 | 2017-01-31 | Flow Forward Medical, Inc. | Blood pump systems and methods |
US9662431B2 (en) | 2010-02-17 | 2017-05-30 | Flow Forward Medical, Inc. | Blood pump systems and methods |
US20110208173A1 (en) * | 2010-02-24 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Treating sleep apnea via renal Denervation |
US8556891B2 (en) | 2010-03-03 | 2013-10-15 | Medtronic Ablation Frontiers Llc | Variable-output radiofrequency ablation power supply |
US8870863B2 (en) | 2010-04-26 | 2014-10-28 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
CN107349009B (en) | 2010-08-05 | 2020-06-26 | 美敦力Af卢森堡有限责任公司 | Cryoablation apparatus, systems, and methods for renal neuromodulation |
WO2012149511A2 (en) | 2011-04-28 | 2012-11-01 | Synecor Llc | Neuromodulation systems and methods for treating acute heart failure syndromes |
US9084610B2 (en) | 2010-10-21 | 2015-07-21 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
CN106377312B (en) | 2010-10-25 | 2019-12-10 | 美敦力Af卢森堡有限责任公司 | Microwave catheter apparatus, systems, and methods for renal neuromodulation |
CN202654229U (en) | 2010-10-25 | 2013-01-09 | 美敦力Af卢森堡有限责任公司 | Catheter device for curing human patients by renal denervation |
JP6046041B2 (en) | 2010-10-25 | 2016-12-14 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | Devices, systems, and methods for neuromodulation therapy evaluation and feedback |
US8945107B2 (en) | 2010-10-26 | 2015-02-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
WO2012068268A2 (en) | 2010-11-17 | 2012-05-24 | Medtronic Ardian Luxembourg S.A.R.L. | Therapeutic renal neuromodulation for treating dyspnea and associated systems and methods |
US8649863B2 (en) | 2010-12-20 | 2014-02-11 | Rainbow Medical Ltd. | Pacemaker with no production |
WO2012148969A2 (en) | 2011-04-25 | 2012-11-01 | Brian Kelly | Apparatus and methods related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
CN102166127B (en) * | 2011-05-13 | 2013-02-06 | 江苏省人民医院 | Renal artery directional blocking device |
US8909316B2 (en) | 2011-05-18 | 2014-12-09 | St. Jude Medical, Cardiology Division, Inc. | Apparatus and method of assessing transvascular denervation |
US9446240B2 (en) | 2011-07-11 | 2016-09-20 | Interventional Autonomics Corporation | System and method for neuromodulation |
US20130072995A1 (en) | 2011-07-11 | 2013-03-21 | Terrance Ransbury | Catheter system for acute neuromodulation |
WO2013028274A2 (en) | 2011-07-11 | 2013-02-28 | Synecor Llc | System and method for neuromodulation |
RU2664156C2 (en) * | 2011-08-17 | 2018-08-15 | Флоу Форвард Медикал, Инк., Сша | System and method for increase of outer diameter of viens and arteries |
KR102215188B1 (en) | 2011-08-17 | 2021-02-17 | 아르티오 메디컬 인크. | Blood pump systems and methods |
EP2872070B1 (en) | 2011-09-09 | 2018-02-07 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
US8855783B2 (en) | 2011-09-09 | 2014-10-07 | Enopace Biomedical Ltd. | Detector-based arterial stimulation |
US9427579B2 (en) | 2011-09-29 | 2016-08-30 | Pacesetter, Inc. | System and method for performing renal denervation verification |
WO2013076588A2 (en) | 2011-11-07 | 2013-05-30 | Medtronic Ardian Luxembourg S.A.R.L. | Endovascular nerve monitoring devices and associated systems and methods |
US9192766B2 (en) | 2011-12-02 | 2015-11-24 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation methods and devices for treatment of polycystic kidney disease |
US8918191B2 (en) | 2011-12-07 | 2014-12-23 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration |
US10188856B1 (en) | 2011-12-07 | 2019-01-29 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US8600505B2 (en) | 2011-12-07 | 2013-12-03 | Cyberonics, Inc. | Implantable device for facilitating control of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US8630709B2 (en) | 2011-12-07 | 2014-01-14 | Cyberonics, Inc. | Computer-implemented system and method for selecting therapy profiles of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US8577458B1 (en) | 2011-12-07 | 2013-11-05 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring |
US8918190B2 (en) | 2011-12-07 | 2014-12-23 | Cyberonics, Inc. | Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction |
US8700150B2 (en) | 2012-01-17 | 2014-04-15 | Cyberonics, Inc. | Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration |
US8571654B2 (en) | 2012-01-17 | 2013-10-29 | Cyberonics, Inc. | Vagus nerve neurostimulator with multiple patient-selectable modes for treating chronic cardiac dysfunction |
US9386991B2 (en) | 2012-02-02 | 2016-07-12 | Rainbow Medical Ltd. | Pressure-enhanced blood flow treatment |
US10342592B2 (en) | 2012-03-07 | 2019-07-09 | Medtronic Ardian Luxembourg S.A.R.L. | Selective modulation of renal nerves |
US9883909B2 (en) | 2012-03-08 | 2018-02-06 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation methods and systems for treatment of hyperaldosteronism |
AU2013230781B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US10737123B2 (en) | 2012-03-08 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the management of pain |
CA2865242A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Biomarker sampling in the context of neuromodulation devices and associated systems and methods |
WO2013134541A2 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Gastrointestinal neuromodulation and associated systems and methods |
US9974593B2 (en) | 2012-03-08 | 2018-05-22 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the treatment of sexual dysfunction |
US8934988B2 (en) | 2012-03-16 | 2015-01-13 | St. Jude Medical Ab | Ablation stent with meander structure |
US9113929B2 (en) | 2012-04-19 | 2015-08-25 | St. Jude Medical, Cardiology Division, Inc. | Non-electric field renal denervation electrode |
US10258791B2 (en) | 2012-04-27 | 2019-04-16 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods |
US9241752B2 (en) | 2012-04-27 | 2016-01-26 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US9848950B2 (en) | 2012-04-27 | 2017-12-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for localized disease treatment by ablation |
US20150088113A1 (en) | 2012-04-27 | 2015-03-26 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
US9943354B2 (en) | 2012-04-27 | 2018-04-17 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for localized inhibition of inflammation by ablation |
MX2014013323A (en) | 2012-05-11 | 2015-01-22 | Medtronic Ardian Luxembourg | Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods. |
WO2013183060A2 (en) | 2012-06-06 | 2013-12-12 | Magenta Medical Ltd. | Prosthetic renal valve |
US8951296B2 (en) | 2012-06-29 | 2015-02-10 | Medtronic Ardian Luxembourg S.A.R.L. | Devices and methods for photodynamically modulating neural function in a human |
US8688212B2 (en) | 2012-07-20 | 2014-04-01 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation |
US10258730B2 (en) | 2012-08-17 | 2019-04-16 | Flow Forward Medical, Inc. | Blood pump systems and methods |
US8612022B1 (en) | 2012-09-13 | 2013-12-17 | Invatec S.P.A. | Neuromodulation catheters and associated systems and methods |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
WO2014066432A2 (en) | 2012-10-22 | 2014-05-01 | Medtronic Ardian Luxembourg Sarl | Catheters with enhanced flexibility and associated devices, systems, and methods |
US9044575B2 (en) | 2012-10-22 | 2015-06-02 | Medtronic Adrian Luxembourg S.a.r.l. | Catheters with enhanced flexibility and associated devices, systems, and methods |
US9643008B2 (en) | 2012-11-09 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation |
US8923964B2 (en) | 2012-11-09 | 2014-12-30 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation |
US9452290B2 (en) | 2012-11-09 | 2016-09-27 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation |
US9095321B2 (en) | 2012-11-21 | 2015-08-04 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices having integral multi-helical balloons and methods of making the same |
US9017317B2 (en) | 2012-12-06 | 2015-04-28 | Medtronic Ardian Luxembourg S.A.R.L. | Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods |
US9179997B2 (en) | 2013-03-06 | 2015-11-10 | St. Jude Medical, Cardiology Division, Inc. | Thermochromic polyvinyl alcohol based hydrogel artery |
EP2777740A3 (en) | 2013-03-12 | 2015-01-21 | St. Jude Medical, Cardiology Division, Inc. | Catheter system |
US10716914B2 (en) | 2013-03-12 | 2020-07-21 | St. Jude Medical, Cardiology Division, Inc. | Catheter system |
US9775966B2 (en) | 2013-03-12 | 2017-10-03 | St. Jude Medical, Cardiology Division, Inc. | Catheter system |
US9510902B2 (en) | 2013-03-13 | 2016-12-06 | St. Jude Medical, Cardiology Division, Inc. | Ablation catheters and systems including rotational monitoring means |
CA3126978A1 (en) * | 2013-03-13 | 2014-09-18 | Magenta Medical Ltd. | Impeller for use with an axial support member |
US10583231B2 (en) | 2013-03-13 | 2020-03-10 | Magenta Medical Ltd. | Blood pump |
US9131982B2 (en) | 2013-03-14 | 2015-09-15 | St. Jude Medical, Cardiology Division, Inc. | Mediguide-enabled renal denervation system for ensuring wall contact and mapping lesion locations |
US8876813B2 (en) | 2013-03-14 | 2014-11-04 | St. Jude Medical, Inc. | Methods, systems, and apparatus for neural signal detection |
US9643011B2 (en) | 2013-03-14 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation |
US9179974B2 (en) | 2013-03-15 | 2015-11-10 | Medtronic Ardian Luxembourg S.A.R.L. | Helical push wire electrode |
US9186212B2 (en) | 2013-03-15 | 2015-11-17 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods utilizing two or more sites along denervation catheter |
US9974477B2 (en) | 2013-03-15 | 2018-05-22 | St. Jude Medical, Cardiology Division, Inc. | Quantification of renal denervation via alterations in renal blood flow pre/post ablation |
EP2967728A1 (en) | 2013-03-15 | 2016-01-20 | St. Jude Medical, Cardiology Division, Inc. | Ablation system, methods, and controllers |
US9066726B2 (en) | 2013-03-15 | 2015-06-30 | Medtronic Ardian Luxembourg S.A.R.L. | Multi-electrode apposition judgment using pressure elements |
US9179973B2 (en) | 2013-03-15 | 2015-11-10 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods for renal denervation utilizing balloon catheter |
WO2014150471A1 (en) | 2013-03-15 | 2014-09-25 | St. Jude Medical, Cardiology Division, Inc. | Ablation system, methods, and controllers |
US10543037B2 (en) | 2013-03-15 | 2020-01-28 | Medtronic Ardian Luxembourg S.A.R.L. | Controlled neuromodulation systems and methods of use |
US10350002B2 (en) | 2013-04-25 | 2019-07-16 | St. Jude Medical, Cardiology Division, Inc. | Electrode assembly for catheter system |
US10548663B2 (en) | 2013-05-18 | 2020-02-04 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices, systems, and methods |
US9872728B2 (en) | 2013-06-28 | 2018-01-23 | St. Jude Medical, Cardiology Division, Inc. | Apparatuses and methods for affixing electrodes to an intravascular balloon |
US20150011991A1 (en) | 2013-07-03 | 2015-01-08 | St. Jude Medical, Cardiology Division, Inc. | Electrode Assembly For Catheter System |
US9326816B2 (en) | 2013-08-30 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods |
US9339332B2 (en) | 2013-08-30 | 2016-05-17 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters with nerve monitoring features for transmitting digital neural signals and associated systems and methods |
US20150073515A1 (en) | 2013-09-09 | 2015-03-12 | Medtronic Ardian Luxembourg S.a.r.I. | Neuromodulation Catheter Devices and Systems Having Energy Delivering Thermocouple Assemblies and Associated Methods |
US9138578B2 (en) | 2013-09-10 | 2015-09-22 | Medtronic Ardian Luxembourg S.A.R.L. | Endovascular catheters with tuned control members and associated systems and methods |
USD914883S1 (en) | 2013-10-23 | 2021-03-30 | St. Jude Medical, Cardiology Division, Inc. | Ablation generator |
US10856936B2 (en) | 2013-10-23 | 2020-12-08 | St. Jude Medical, Cardiology Division, Inc. | Electrode assembly for catheter system including thermoplastic-based struts |
USD747491S1 (en) | 2013-10-23 | 2016-01-12 | St. Jude Medical, Cardiology Division, Inc. | Ablation generator |
US10433902B2 (en) | 2013-10-23 | 2019-10-08 | Medtronic Ardian Luxembourg S.A.R.L. | Current control methods and systems |
USD774043S1 (en) | 2013-10-23 | 2016-12-13 | St. Jude Medical, Cardiology Division, Inc. | Display screen with graphical user interface for ablation generator |
WO2015061052A1 (en) | 2013-10-24 | 2015-04-30 | St. Jude Medical, Cardiology Division, Inc. | Flexible catheter shaft and method of manufacture |
US9999748B2 (en) | 2013-10-24 | 2018-06-19 | St. Jude Medical, Cardiology Division, Inc. | Flexible catheter shaft and method of manufacture |
US10034705B2 (en) | 2013-10-24 | 2018-07-31 | St. Jude Medical, Cardiology Division, Inc. | High strength electrode assembly for catheter system including novel electrode |
WO2015065636A1 (en) | 2013-10-28 | 2015-05-07 | St. Jude Medical, Cardiology Division, Inc. | Electrode assembly for catheter system including interlinked struts |
US9999773B2 (en) | 2013-10-30 | 2018-06-19 | Cyberonics, Inc. | Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters |
US9861433B2 (en) | 2013-11-05 | 2018-01-09 | St. Jude Medical, Cardiology Division, Inc. | Helical-shaped ablation catheter and methods of use |
EP3065673A4 (en) | 2013-11-06 | 2017-07-12 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
US9764113B2 (en) | 2013-12-11 | 2017-09-19 | Magenta Medical Ltd | Curved catheter |
US9511228B2 (en) | 2014-01-14 | 2016-12-06 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation |
US10166069B2 (en) | 2014-01-27 | 2019-01-01 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters having jacketed neuromodulation elements and related devices, systems, and methods |
US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
US10463424B2 (en) | 2014-03-11 | 2019-11-05 | Medtronic Ardian Luxembourg S.A.R.L. | Catheters with independent radial-expansion members and associated devices, systems, and methods |
US9579149B2 (en) | 2014-03-13 | 2017-02-28 | Medtronic Ardian Luxembourg S.A.R.L. | Low profile catheter assemblies and associated systems and methods |
US9409024B2 (en) | 2014-03-25 | 2016-08-09 | Cyberonics, Inc. | Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction |
US9950169B2 (en) | 2014-04-25 | 2018-04-24 | Cyberonics, Inc. | Dynamic stimulation adjustment for identification of a neural fulcrum |
US9272143B2 (en) | 2014-05-07 | 2016-03-01 | Cyberonics, Inc. | Responsive neurostimulation for the treatment of chronic cardiac dysfunction |
US9415224B2 (en) | 2014-04-25 | 2016-08-16 | Cyberonics, Inc. | Neurostimulation and recording of physiological response for the treatment of chronic cardiac dysfunction |
US9713719B2 (en) | 2014-04-17 | 2017-07-25 | Cyberonics, Inc. | Fine resolution identification of a neural fulcrum for the treatment of chronic cardiac dysfunction |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
EP2937053A1 (en) | 2014-04-24 | 2015-10-28 | St. Jude Medical, Cardiology Division, Inc. | Ablation systems including pulse rate detector and feedback mechanism and methods of use |
EP4371512A3 (en) | 2014-04-24 | 2024-08-14 | Medtronic Ardian Luxembourg S.à.r.l. | Neuromodulation catheters having braided shafts and associated systems and methods |
US10610292B2 (en) | 2014-04-25 | 2020-04-07 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology |
US9980813B2 (en) | 2014-04-28 | 2018-05-29 | Cook Medical Technologies Llc | Selective fluid barrier valve device and method of treatment |
US10709490B2 (en) | 2014-05-07 | 2020-07-14 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods |
IL250181B2 (en) | 2014-07-20 | 2024-04-01 | Bruckheimer Elchanan | Pulmonary artery implant apparatus |
US9533153B2 (en) | 2014-08-12 | 2017-01-03 | Cyberonics, Inc. | Neurostimulation titration process |
US9770599B2 (en) | 2014-08-12 | 2017-09-26 | Cyberonics, Inc. | Vagus nerve stimulation and subcutaneous defibrillation system |
US9737716B2 (en) | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
WO2016033543A1 (en) | 2014-08-28 | 2016-03-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for assessing efficacy of renal neuromodulation and associated systems and devices |
JP6466120B2 (en) * | 2014-09-24 | 2019-02-06 | 学校法人大阪医科薬科大学 | Artificial blood flow control device |
EP4389044A3 (en) | 2014-10-01 | 2024-09-11 | Medtronic Ardian Luxembourg S.à.r.l. | Systems and methods for evaluating neuromodulation therapy via hemodynamic responses |
US10039552B2 (en) | 2014-10-28 | 2018-08-07 | Cook Medical Technologies Llc | Magnetically actuated gating devices, systems, kits, and methods |
US10925579B2 (en) | 2014-11-05 | 2021-02-23 | Otsuka Medical Devices Co., Ltd. | Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery |
US9504832B2 (en) | 2014-11-12 | 2016-11-29 | Cyberonics, Inc. | Neurostimulation titration process via adaptive parametric modification |
EP3943032A1 (en) | 2014-11-14 | 2022-01-26 | Medtronic Ardian Luxembourg S.à.r.l. | Catheter apparatuses for modulation of nerves in communication with the pulmonary system and associated systems |
WO2016100720A1 (en) | 2014-12-17 | 2016-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing sympathetic nervous system tone for renal neuromodulation therapy |
WO2016185473A1 (en) | 2015-05-18 | 2016-11-24 | Magenta Medical Ltd. | Blood pump |
US10736692B2 (en) | 2016-04-28 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the treatment of cancer |
KR20190013788A (en) | 2016-04-29 | 2019-02-11 | 플로우 포워드 메디컬, 인크. | Systems and methods of using tube ends and tube ends |
US11439460B2 (en) | 2016-06-23 | 2022-09-13 | St. Jude Medical, Cardiology Division, Inc. | Catheter system and electrode assembly for intraprocedural evaluation of renal denervation |
US11771434B2 (en) | 2016-09-28 | 2023-10-03 | Restore Medical Ltd. | Artery medical apparatus and methods of use thereof |
US11039915B2 (en) | 2016-09-29 | 2021-06-22 | Magenta Medical Ltd. | Blood vessel tube |
EP3519008A4 (en) | 2016-10-03 | 2020-08-26 | Queen Mary University of London | Mechanical circulatory support device with axial flow turbomachine optimized for heart failure and cardio-renal syndrome |
EP3556409B1 (en) | 2016-10-25 | 2022-01-05 | Magenta Medical Ltd. | Ventricular assist device |
US10231784B2 (en) | 2016-10-28 | 2019-03-19 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics |
CN110049792B (en) | 2016-11-23 | 2022-01-18 | 马真塔医药有限公司 | Blood pump |
US10646713B2 (en) | 2017-02-22 | 2020-05-12 | Medtronic Ardian Luxembourg S.A.R.L. | Systems, devices, and associated methods for treating patients via renal neuromodulation to reduce a risk of developing cognitive impairment |
WO2018223060A1 (en) | 2017-06-01 | 2018-12-06 | Queen Mary University Of London | Mechanical circulatory support device with centrifugal impeller designed for implantation in the descending aorta |
CN110691554B (en) | 2017-06-05 | 2022-11-01 | 恢复医疗有限公司 | Double-walled fixed-length stent-like device and method of use |
EP3638336B1 (en) | 2018-01-10 | 2022-04-06 | Magenta Medical Ltd. | Ventricular assist device |
US10905808B2 (en) | 2018-01-10 | 2021-02-02 | Magenta Medical Ltd. | Drive cable for use with a blood pump |
US12082917B2 (en) | 2018-01-24 | 2024-09-10 | Medtronic Ireland Manufacturing Unlimited Company | Systems, devices, and methods for assessing efficacy of renal neuromodulation therapy |
US10893927B2 (en) | 2018-03-29 | 2021-01-19 | Magenta Medical Ltd. | Inferior vena cava blood-flow implant |
US11116959B2 (en) | 2018-04-04 | 2021-09-14 | Theodosios Alexander | Removable mechanical circulatory support for short term use |
EP3782667B1 (en) | 2019-01-24 | 2022-04-06 | Magenta Medical Ltd. | Impeller and frame of a blood pump |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
USD1023035S1 (en) * | 2022-05-25 | 2024-04-16 | K-Bio HealthCare, Inc. | Display screen or portion thereof with graphical user interface |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014318A (en) * | 1973-08-20 | 1977-03-29 | Dockum James M | Circulatory assist device and system |
US4154227A (en) * | 1977-10-11 | 1979-05-15 | Krause Horst E | Method and apparatus for pumping blood within a vessel |
US4256094A (en) * | 1979-06-18 | 1981-03-17 | Kapp John P | Arterial pressure control system |
US4284073A (en) * | 1977-10-11 | 1981-08-18 | Krause Horst E | Method and apparatus for pumping blood within a vessel |
US4753221A (en) * | 1986-10-22 | 1988-06-28 | Intravascular Surgical Instruments, Inc. | Blood pumping catheter and method of use |
US4881939A (en) * | 1985-02-19 | 1989-11-21 | The Johns Hopkins University | Implantable helical cuff |
US5372573A (en) * | 1989-06-20 | 1994-12-13 | British Technology Group Limited | Blood flow |
US5505701A (en) * | 1993-11-22 | 1996-04-09 | Anaya Fernandez De Lomana; Eugenio F. | Intra-aortic balloon catheter |
US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6086527A (en) * | 1998-04-02 | 2000-07-11 | Scimed Life Systems, Inc. | System for treating congestive heart failure |
US6231551B1 (en) * | 1999-03-01 | 2001-05-15 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US20020107536A1 (en) * | 2001-02-07 | 2002-08-08 | Hussein Hany M. | Device and method for preventing kidney failure |
US6514226B1 (en) * | 2000-02-10 | 2003-02-04 | Chf Solutions, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney |
US20030083617A1 (en) * | 1999-03-01 | 2003-05-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for renal and coronary perfusion augmentation |
US6592567B1 (en) * | 1999-12-07 | 2003-07-15 | Chf Solutions, Inc. | Kidney perfusion catheter |
US6616624B1 (en) * | 2000-10-30 | 2003-09-09 | Cvrx, Inc. | Systems and method for controlling renovascular perfusion |
US20040064090A1 (en) * | 1999-01-11 | 2004-04-01 | Gad Keren | Apparatus and methods for treating congestive heart disease |
US20040064091A1 (en) * | 1999-01-11 | 2004-04-01 | Gad Keren | Apparatus and methods for treating congestive heart disease |
US20070060972A1 (en) * | 2000-09-27 | 2007-03-15 | Cvrx, Inc. | Devices and methods for cardiovascular reflex treatments |
US7499747B2 (en) * | 2004-03-02 | 2009-03-03 | Cvrx, Inc. | External baroreflex activation |
US20100125288A1 (en) * | 2008-11-17 | 2010-05-20 | G&L Consulting, Llc | Method and apparatus for reducing renal blood pressure |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE346468B (en) | 1969-02-24 | 1972-07-10 | Lkb Medical Ab | |
US3943936A (en) | 1970-09-21 | 1976-03-16 | Rasor Associates, Inc. | Self powered pacers and stimulators |
US3768102A (en) | 1972-02-03 | 1973-10-30 | Univ Utah | Implantable artificial urethral valve |
US4053952A (en) | 1975-10-10 | 1977-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health, Education And Welfare | Magnetic fluid actuated control valve, relief valve and pump |
US4130119A (en) | 1977-04-01 | 1978-12-19 | Barlow Mfg. Corp. | Occlusion device |
US4192302A (en) * | 1978-09-12 | 1980-03-11 | Boddie Arthur W | Hepatic isolation and perfusion circuit assembly |
US4417360A (en) | 1981-07-31 | 1983-11-29 | Manoutchehr Moasser | Nontraumatic prosthetic valve with magnetic closure |
FR2534801A1 (en) | 1982-10-21 | 1984-04-27 | Claracq Michel | DEVICE FOR PARTIALLY OCCLUDING A VESSEL, PARTICULARLY OF THE CAUDAL CAVE VEIN, AND CONSTITUENT PART THEREOF |
US4551862A (en) | 1982-12-15 | 1985-11-12 | Haber Terry M | Prosthetic sphincter |
US4887608A (en) | 1986-01-31 | 1989-12-19 | Boston Scientific Corporation | Method and apparatus for estimating tissue damage |
US4969470A (en) | 1984-02-27 | 1990-11-13 | Boston Scientific Corporation | Heart analysis using pressure-controlled intermittent coronary sinus occlusion |
US4682583A (en) | 1984-04-13 | 1987-07-28 | Burton John H | Inflatable artificial sphincter |
US4710164A (en) * | 1984-05-01 | 1987-12-01 | Henry Ford Hospital | Automated hemodialysis control based upon patient blood pressure and heart rate |
US4828544A (en) | 1984-09-05 | 1989-05-09 | Quotidian No. 100 Pty Limited | Control of blood flow |
US4709690A (en) | 1986-04-21 | 1987-12-01 | Habley Medical Technology Corporation | Implantable blood flow and occlusion pressure sensing sphincteric system |
US4781672A (en) | 1986-10-21 | 1988-11-01 | Cordis Corporation | Three stage implantable flow control valve with improved valve closure member |
US4902272A (en) | 1987-06-17 | 1990-02-20 | Abiomed Cardiovascular, Inc. | Intra-arterial cardiac support system |
US4877035A (en) | 1988-10-12 | 1989-10-31 | Trustees Of The University Of Pennsylvania | Measurement of the end-systolic pressure-volume relation using intraaortic balloon occlusion |
US5019055A (en) | 1989-12-22 | 1991-05-28 | Boyle Matthew O | Flow regulator and method |
US5203348A (en) | 1990-06-06 | 1993-04-20 | Cardiac Pacemakers, Inc. | Subcutaneous defibrillation electrodes |
US5135474A (en) * | 1990-08-03 | 1992-08-04 | University Of Medicine And Dentistry Of New Jersey | Hepatic bypass catheter |
US5199428A (en) | 1991-03-22 | 1993-04-06 | Medtronic, Inc. | Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload |
US5251634A (en) | 1991-05-03 | 1993-10-12 | Cyberonics, Inc. | Helical nerve electrode |
US5215089A (en) | 1991-10-21 | 1993-06-01 | Cyberonics, Inc. | Electrode assembly for nerve stimulation |
US6224619B1 (en) * | 1991-12-17 | 2001-05-01 | Heartport, Inc. | Blood vessel occlusion trocar having size and shape varying insertion body |
US5330515A (en) | 1992-06-17 | 1994-07-19 | Cyberonics, Inc. | Treatment of pain by vagal afferent stimulation |
DE4331658B4 (en) | 1993-09-17 | 2009-12-10 | Eska Medical Gmbh & Co | Implantable device for selectively opening and closing tubular body organs, in particular the urethra |
US5527159A (en) | 1993-11-10 | 1996-06-18 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Rotary blood pump |
US5590649A (en) * | 1994-04-15 | 1997-01-07 | Vital Insite, Inc. | Apparatus and method for measuring an induced perturbation to determine blood pressure |
US5785659A (en) | 1994-04-15 | 1998-07-28 | Vital Insite, Inc. | Automatically activated blood pressure measurement device |
US5484385A (en) * | 1994-04-21 | 1996-01-16 | C. R. Bard, Inc. | Intra-aortic balloon catheter |
US5509888A (en) | 1994-07-26 | 1996-04-23 | Conceptek Corporation | Controller valve device and method |
US5540734A (en) | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5540735A (en) | 1994-12-12 | 1996-07-30 | Rehabilicare, Inc. | Apparatus for electro-stimulation of flexing body portions |
US5643172A (en) * | 1995-03-06 | 1997-07-01 | Abiomed R & D, Inc. | Tubular circulatory assist device |
DE19514638C2 (en) * | 1995-04-20 | 1998-06-04 | Peter Dr Med Boekstegers | Device for the selective suction and retroinfusion of a fluid from or into body veins controlled by venous pressure |
US5707400A (en) | 1995-09-19 | 1998-01-13 | Cyberonics, Inc. | Treating refractory hypertension by nerve stimulation |
US5700282A (en) | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
US6073048A (en) | 1995-11-17 | 2000-06-06 | Medtronic, Inc. | Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure |
WO1997026894A1 (en) | 1996-01-25 | 1997-07-31 | Weglicki William B | Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution |
US5813410A (en) | 1996-02-01 | 1998-09-29 | Levin; John M. | Internal body pump and systems employing same |
US5727558A (en) | 1996-02-14 | 1998-03-17 | Hakki; A-Hamid | Noninvasive blood pressure monitor and control device |
FR2744924B1 (en) * | 1996-02-21 | 1998-04-24 | Franchi Pierre | PRESSURE GENERATOR / REGULATOR DEVICE FOR AN IMPLANTABLE HEART ASSISTANCE PUMP OF THE COUNTERPRESSURE BALLOON TYPE |
US5766236A (en) | 1996-04-19 | 1998-06-16 | Detty; Gerald D. | Electrical stimulation support braces |
RU2119788C1 (en) * | 1996-09-30 | 1998-10-10 | Жукова Елена Юрьевна | Method of recovery of peripheral nerve functions |
US5885271A (en) * | 1997-03-14 | 1999-03-23 | Millennium Cardiac Strategies, Inc. | Device for regional immobilization of a compliant body |
US5861015A (en) | 1997-05-05 | 1999-01-19 | Benja-Athon; Anuthep | Modulation of the nervous system for treatment of pain and related disorders |
US5954766A (en) | 1997-09-16 | 1999-09-21 | Zadno-Azizi; Gholam-Reza | Body fluid flow control device |
US6699231B1 (en) * | 1997-12-31 | 2004-03-02 | Heartport, Inc. | Methods and apparatus for perfusion of isolated tissue structure |
US6564101B1 (en) | 1998-02-02 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Electrical system for weight loss and laparoscopic implanation thereof |
US5891012A (en) | 1998-05-21 | 1999-04-06 | My-Tech, Inc. | Coronary artery counterpulsation device and method |
IL124787A0 (en) * | 1998-06-07 | 1999-01-26 | Itamar Medical C M 1997 Ltd | Pressure applicator devices particularly useful for non-invasive detection of medical conditions |
US7122019B1 (en) * | 2000-11-28 | 2006-10-17 | Flowmedica Inc. | Intra-aortic renal drug delivery catheter |
US7329236B2 (en) * | 1999-01-11 | 2008-02-12 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6178349B1 (en) | 1999-04-15 | 2001-01-23 | Medtronic, Inc. | Drug delivery neural stimulation device for treatment of cardiovascular disorders |
US6241743B1 (en) * | 1999-05-13 | 2001-06-05 | Intellicardia, Inc. | Anastomosis device and method |
US6438428B1 (en) | 1999-10-27 | 2002-08-20 | Axelgaard Manufacturing Co., Ltd. | Electrical stimulation compress |
US6468200B1 (en) * | 2000-03-06 | 2002-10-22 | Michael C. Fischi | Segmented peristaltic intra-aortic balloon pump |
US6287608B1 (en) * | 2000-04-11 | 2001-09-11 | Intellicardia, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney by infusion of a vasodilator |
AU2000254982A1 (en) * | 2000-06-20 | 2002-01-02 | Intellicardia, Inc. | Instrumented stent |
DE20012378U1 (en) | 2000-07-17 | 2000-10-19 | Leica Microsystems Heidelberg Gmbh, 68165 Mannheim | Arrangement for spectrally sensitive incident and transmitted light illumination |
US20020103516A1 (en) | 2000-09-20 | 2002-08-01 | Patwardhan Ravish Vinay | Carotid sinus nerve stimulation for epilepsy control |
WO2002070039A2 (en) | 2001-03-01 | 2002-09-12 | Three Arch Partners | Intravascular device for treatment of hypertension |
US20020151051A1 (en) | 2001-03-27 | 2002-10-17 | Sheng Feng Li | Compositions and methods for isolating genes comprising subcellular localization sequences |
US6600956B2 (en) | 2001-08-21 | 2003-07-29 | Cyberonics, Inc. | Circumneural electrode assembly |
US6978174B2 (en) * | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7162303B2 (en) * | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
AU2003300779A1 (en) * | 2002-09-20 | 2004-05-04 | Flowmedica, Inc. | Catheter system for renal therapy |
US7063679B2 (en) * | 2002-09-20 | 2006-06-20 | Flowmedica, Inc. | Intra-aortic renal delivery catheter |
WO2007127477A2 (en) * | 2006-04-27 | 2007-11-08 | Synecor, Llc | Renal blood flow augmentation for congestive heart failure treatment |
-
2000
- 2000-10-30 US US09/702,089 patent/US6616624B1/en not_active Expired - Lifetime
-
2003
- 2003-06-02 US US10/453,678 patent/US7485104B2/en not_active Expired - Lifetime
-
2008
- 2008-12-29 US US12/345,095 patent/US20090105631A1/en not_active Abandoned
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014318A (en) * | 1973-08-20 | 1977-03-29 | Dockum James M | Circulatory assist device and system |
US4154227A (en) * | 1977-10-11 | 1979-05-15 | Krause Horst E | Method and apparatus for pumping blood within a vessel |
US4284073A (en) * | 1977-10-11 | 1981-08-18 | Krause Horst E | Method and apparatus for pumping blood within a vessel |
US4256094A (en) * | 1979-06-18 | 1981-03-17 | Kapp John P | Arterial pressure control system |
US4881939A (en) * | 1985-02-19 | 1989-11-21 | The Johns Hopkins University | Implantable helical cuff |
US4753221A (en) * | 1986-10-22 | 1988-06-28 | Intravascular Surgical Instruments, Inc. | Blood pumping catheter and method of use |
US5372573A (en) * | 1989-06-20 | 1994-12-13 | British Technology Group Limited | Blood flow |
US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5505701A (en) * | 1993-11-22 | 1996-04-09 | Anaya Fernandez De Lomana; Eugenio F. | Intra-aortic balloon catheter |
US6086527A (en) * | 1998-04-02 | 2000-07-11 | Scimed Life Systems, Inc. | System for treating congestive heart failure |
US6749598B1 (en) * | 1999-01-11 | 2004-06-15 | Flowmedica, Inc. | Apparatus and methods for treating congestive heart disease |
US20040064090A1 (en) * | 1999-01-11 | 2004-04-01 | Gad Keren | Apparatus and methods for treating congestive heart disease |
US7780628B1 (en) * | 1999-01-11 | 2010-08-24 | Angiodynamics, Inc. | Apparatus and methods for treating congestive heart disease |
US20040064091A1 (en) * | 1999-01-11 | 2004-04-01 | Gad Keren | Apparatus and methods for treating congestive heart disease |
US20030083617A1 (en) * | 1999-03-01 | 2003-05-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for renal and coronary perfusion augmentation |
US6231551B1 (en) * | 1999-03-01 | 2001-05-15 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US6592567B1 (en) * | 1999-12-07 | 2003-07-15 | Chf Solutions, Inc. | Kidney perfusion catheter |
US6514226B1 (en) * | 2000-02-10 | 2003-02-04 | Chf Solutions, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney |
US20070060972A1 (en) * | 2000-09-27 | 2007-03-15 | Cvrx, Inc. | Devices and methods for cardiovascular reflex treatments |
US20070167984A1 (en) * | 2000-09-27 | 2007-07-19 | Cvrx, Inc. | Method and apparatus for stimulation of baroreceptors |
US20080177349A1 (en) * | 2000-09-27 | 2008-07-24 | Cvrx, Inc. | Apparatus and method for modulating the baroreflex system |
US6616624B1 (en) * | 2000-10-30 | 2003-09-09 | Cvrx, Inc. | Systems and method for controlling renovascular perfusion |
US7485104B2 (en) * | 2000-10-30 | 2009-02-03 | Cvrx, Inc. | Systems and methods for controlling renovascular perfusion |
US20020107536A1 (en) * | 2001-02-07 | 2002-08-08 | Hussein Hany M. | Device and method for preventing kidney failure |
US7499747B2 (en) * | 2004-03-02 | 2009-03-03 | Cvrx, Inc. | External baroreflex activation |
US20100125288A1 (en) * | 2008-11-17 | 2010-05-20 | G&L Consulting, Llc | Method and apparatus for reducing renal blood pressure |
Cited By (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9713483B2 (en) | 1995-10-13 | 2017-07-25 | Medtronic Vascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US10130792B2 (en) | 2002-04-08 | 2018-11-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs |
US10179027B2 (en) | 2002-04-08 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable baskets for renal neuromodulation and associated systems and methods |
US10179235B2 (en) | 2002-04-08 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US9463066B2 (en) | 2002-04-08 | 2016-10-11 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation |
US9968611B2 (en) | 2002-04-08 | 2018-05-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US10272246B2 (en) | 2002-04-08 | 2019-04-30 | Medtronic Adrian Luxembourg S.a.r.l | Methods for extravascular renal neuromodulation |
US10376516B2 (en) | 2002-04-08 | 2019-08-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US9814873B2 (en) | 2002-04-08 | 2017-11-14 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US10034708B2 (en) | 2002-04-08 | 2018-07-31 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for thermally-induced renal neuromodulation |
US10441356B2 (en) | 2002-04-08 | 2019-10-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation via neuromodulatory agents |
US10124195B2 (en) | 2002-04-08 | 2018-11-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermally-induced renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US10850091B2 (en) | 2002-04-08 | 2020-12-01 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US9510901B2 (en) | 2003-09-12 | 2016-12-06 | Vessix Vascular, Inc. | Selectable eccentric remodeling and/or ablation |
US9125666B2 (en) | 2003-09-12 | 2015-09-08 | Vessix Vascular, Inc. | Selectable eccentric remodeling and/or ablation of atherosclerotic material |
US10188457B2 (en) | 2003-09-12 | 2019-01-29 | Vessix Vascular, Inc. | Selectable eccentric remodeling and/or ablation |
US9125667B2 (en) | 2004-09-10 | 2015-09-08 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US8939970B2 (en) | 2004-09-10 | 2015-01-27 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US10350004B2 (en) | 2004-12-09 | 2019-07-16 | Twelve, Inc. | Intravascular treatment catheters |
US11272982B2 (en) | 2004-12-09 | 2022-03-15 | Twelve, Inc. | Intravascular treatment catheters |
US9486355B2 (en) | 2005-05-03 | 2016-11-08 | Vessix Vascular, Inc. | Selective accumulation of energy with or without knowledge of tissue topography |
US8231552B2 (en) * | 2005-12-22 | 2012-07-31 | P. Square Medical Ltd. | Urethral blockage diagnosis |
US20080312538A1 (en) * | 2005-12-22 | 2008-12-18 | P. Square Medical Ltd. | Urethral Blockage Diagnosis |
US20080262389A1 (en) * | 2005-12-22 | 2008-10-23 | P. Square Medical Ltd. | Monitoring conditions of a patient's urinary system |
US9808300B2 (en) | 2006-05-02 | 2017-11-07 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
US9974607B2 (en) | 2006-10-18 | 2018-05-22 | Vessix Vascular, Inc. | Inducing desirable temperature effects on body tissue |
US10213252B2 (en) | 2006-10-18 | 2019-02-26 | Vessix, Inc. | Inducing desirable temperature effects on body tissue |
US10413356B2 (en) | 2006-10-18 | 2019-09-17 | Boston Scientific Scimed, Inc. | System for inducing desirable temperature effects on body tissue |
US20110125061A1 (en) * | 2006-12-20 | 2011-05-26 | P Square Medical Ltd. | Monitoring Conditions Of A Patient's Urinary System |
US9656009B2 (en) | 2007-07-11 | 2017-05-23 | California Institute Of Technology | Cardiac assist system using helical arrangement of contractile bands and helically-twisting cardiac assist device |
US9327100B2 (en) | 2008-11-14 | 2016-05-03 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US9277955B2 (en) | 2010-04-09 | 2016-03-08 | Vessix Vascular, Inc. | Power generating and control apparatus for the treatment of tissue |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US8632343B2 (en) * | 2010-05-19 | 2014-01-21 | C. R. Bard, Inc. | Demonstration mannequin for simulating catheter malposition |
US20110287398A1 (en) * | 2010-05-19 | 2011-11-24 | C. R. Bard, Inc. | Demonstration mannequin for simulating catheter malposition |
US8880185B2 (en) | 2010-06-11 | 2014-11-04 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US9125655B2 (en) | 2010-07-16 | 2015-09-08 | California Institute Of Technology | Correction and optimization of wave reflection in blood vessels |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
US9848946B2 (en) | 2010-11-15 | 2017-12-26 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
US9649156B2 (en) | 2010-12-15 | 2017-05-16 | Boston Scientific Scimed, Inc. | Bipolar off-wall electrode device for renal nerve ablation |
US9220561B2 (en) | 2011-01-19 | 2015-12-29 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
US9919144B2 (en) | 2011-04-08 | 2018-03-20 | Medtronic Adrian Luxembourg S.a.r.l. | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
US9579030B2 (en) | 2011-07-20 | 2017-02-28 | Boston Scientific Scimed, Inc. | Percutaneous devices and methods to visualize, target and ablate nerves |
US9186209B2 (en) | 2011-07-22 | 2015-11-17 | Boston Scientific Scimed, Inc. | Nerve modulation system having helical guide |
US9186210B2 (en) | 2011-10-10 | 2015-11-17 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
US10085799B2 (en) | 2011-10-11 | 2018-10-02 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US9079000B2 (en) | 2011-10-18 | 2015-07-14 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
WO2013070186A1 (en) * | 2011-11-07 | 2013-05-16 | California Institute Of Technology | Correction and optimization of wave reflection in blood vessels |
US8951251B2 (en) | 2011-11-08 | 2015-02-10 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
US9186211B2 (en) | 2011-12-23 | 2015-11-17 | Boston Scientific Scimed, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9028472B2 (en) | 2011-12-23 | 2015-05-12 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9072902B2 (en) | 2011-12-23 | 2015-07-07 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9174050B2 (en) | 2011-12-23 | 2015-11-03 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9037259B2 (en) | 2011-12-23 | 2015-05-19 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9402684B2 (en) | 2011-12-23 | 2016-08-02 | Boston Scientific Scimed, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9592386B2 (en) | 2011-12-23 | 2017-03-14 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9433760B2 (en) | 2011-12-28 | 2016-09-06 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
US10321946B2 (en) | 2012-08-24 | 2019-06-18 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices with weeping RF ablation balloons |
US9173696B2 (en) | 2012-09-17 | 2015-11-03 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
US10835305B2 (en) | 2012-10-10 | 2020-11-17 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices and methods |
US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9693821B2 (en) | 2013-03-11 | 2017-07-04 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
US9297845B2 (en) | 2013-03-15 | 2016-03-29 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
US9827039B2 (en) | 2013-03-15 | 2017-11-28 | Boston Scientific Scimed, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US10022182B2 (en) | 2013-06-21 | 2018-07-17 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation having rotatable shafts |
US9943365B2 (en) | 2013-06-21 | 2018-04-17 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
US9833283B2 (en) | 2013-07-01 | 2017-12-05 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US10660698B2 (en) | 2013-07-11 | 2020-05-26 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
US10413357B2 (en) | 2013-07-11 | 2019-09-17 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
US9925001B2 (en) | 2013-07-19 | 2018-03-27 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
US10342609B2 (en) | 2013-07-22 | 2019-07-09 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US10695124B2 (en) | 2013-07-22 | 2020-06-30 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
US10722300B2 (en) | 2013-08-22 | 2020-07-28 | Boston Scientific Scimed, Inc. | Flexible circuit having improved adhesion to a renal nerve modulation balloon |
US9895194B2 (en) | 2013-09-04 | 2018-02-20 | Boston Scientific Scimed, Inc. | Radio frequency (RF) balloon catheter having flushing and cooling capability |
US10952790B2 (en) | 2013-09-13 | 2021-03-23 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
US9687166B2 (en) | 2013-10-14 | 2017-06-27 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
US9962223B2 (en) | 2013-10-15 | 2018-05-08 | Boston Scientific Scimed, Inc. | Medical device balloon |
US10945786B2 (en) | 2013-10-18 | 2021-03-16 | Boston Scientific Scimed, Inc. | Balloon catheters with flexible conducting wires and related methods of use and manufacture |
US10271898B2 (en) | 2013-10-25 | 2019-04-30 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
US11202671B2 (en) | 2014-01-06 | 2021-12-21 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
US9907609B2 (en) | 2014-02-04 | 2018-03-06 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
US20180206974A1 (en) * | 2017-01-25 | 2018-07-26 | W. L. Gore & Associates, Inc. | Method and device for treatment and prevention of fluid overload in patients with heart failure |
US11510679B2 (en) | 2017-09-21 | 2022-11-29 | W. L. Gore & Associates, Inc. | Multiple inflation endovascular medical device |
US11166676B2 (en) * | 2017-12-11 | 2021-11-09 | Marina I. Adrianzen Fonseca | Real-time kidney monitoring medical device |
US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
US11883030B2 (en) | 2022-04-29 | 2024-01-30 | inQB8 Medical Technologies, LLC | Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature |
US11974751B2 (en) | 2022-04-29 | 2024-05-07 | inQB8 Medical Technologies, LLC | Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature |
Also Published As
Publication number | Publication date |
---|---|
US20030199806A1 (en) | 2003-10-23 |
US7485104B2 (en) | 2009-02-03 |
US6616624B1 (en) | 2003-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7485104B2 (en) | Systems and methods for controlling renovascular perfusion | |
US8382695B1 (en) | Method and apparatus for treatment of congestive heart disease | |
US20230241361A1 (en) | Systems and methods for selectively occluding the superior vena cava for treating heart conditions | |
US6428464B1 (en) | Implantable heart assist system | |
US6514226B1 (en) | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney | |
US6083215A (en) | Method and apparatus for antegrade coronary perfusion | |
US7244225B2 (en) | Devices and methods for non-invasively improving blood circulation | |
US7458929B2 (en) | Implantable heart assist system and method of applying same | |
US7766892B2 (en) | Apparatus and methods for treating congestive heart disease | |
US5135467A (en) | Implantable system and method for coronary perfusions assistance | |
US6685621B2 (en) | Implantable heart assist system and method of applying same | |
CN111699008B (en) | Systems and methods for selectively occluding a superior vena cava to treat heart conditions | |
JP3265650B2 (en) | Blood circulation assist device | |
US20040064091A1 (en) | Apparatus and methods for treating congestive heart disease | |
JP2020501637A (en) | Intracranial volume adapter for cerebral blood flow | |
Yambe et al. | Effect of left ventricular assistance on sympathetic tone | |
CN114980955A (en) | Systems and methods for selectively occluding a superior vena cava to treat a cardiac condition | |
Solanki | Aortic counterpulsation: C-pulse and other devices for cardiac support | |
WO2004054641A1 (en) | Blood pumping system and procedure | |
Dormandy et al. | Hemodynamics and coronary blood flow with counterpulsation | |
US20220361884A1 (en) | Venous valve apparatuses and methods for controlling blood flow | |
Goetz et al. | Unidirectional intraaortic balloon pumping in cardiogenic shock and intractable left ventricular failure | |
JP2023122675A (en) | Novel intraaortic balloon block device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CVRX, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIEVAL, ROBERT S.;REEL/FRAME:022541/0363 Effective date: 20090119 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CVRX, INC., MINNESOTA Free format text: CONFIRMATORY ASSIGNMENT;ASSIGNOR:CVRX, INC.;REEL/FRAME:027875/0557 Effective date: 20120112 |